

Supporting Information:

GNE-886: A Potent and Selective Inhibitor of the Cat Eye

Syndrome Chromosome Region Candidate 2 Bromodomain

Terry D. Crawford,^{†} James E. Audia,[‡] Steve Bellon,[‡] Daniel J. Burdick,[†] Archana Bommi-Reddy,[‡] Alexandre Côté,[‡] Richard T. Cummings,[‡] Martin Duplessis,[‡] E. Megan Flynn,[†] Michael Hewitt,[‡] Hon-Ren Huang,[‡] Hariharan Jayaran,[‡] Ying Jiang,[§] Shivangi Joshi,[‡] James R. Kiefer,[†] Jeremy Murray,[†] Christopher G. Nasveschuk,[‡] Arianne Neiss,[‡] Eneida Pardo,[‡] F. Anthony Romero,[†] Peter Sandy,[‡] Robert J. Sims III,[‡] Yong Tang,[‡] Alexander M. Taylor,[‡] Vickie Tsui,[†] Jian Wang,[§] Shumei Wang,[†] Yongyun Wang,[§] Zhaowu Xu,[§] Laura Zawadzke,[‡] Xiaoqin Zhu,[§] Brian K. Albrecht,[‡] Steven R. Magnuson,[†] Andrea G. Cochran[†]*

[†]Genentech Inc., 1 DNA Way, South San Francisco, CA 94080

[‡]Constellation Pharmaceuticals, 215 First Street, Suite 200, Cambridge, MA 02142

[§]Wuxi Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China

Table of Contents

	Page
Protein and assay methods	S3
Synthesis of biotinylated probes for TR-FRET assays	S3
CECR2 bromodomain cellular assay	S3
Crystallography Methods	S3
Table S1. Crystallographic data collection and refinement statistics	S4
Figure S1. Compound 6 bound to CECR2, overlaid with Apo structure residues.	S5
Table S2. Assay data with standard deviations	S6
Figure S2, S3. CECR2 dot images for compound 21.	S7
Table S3. Raw CECR2 dot data for Compound 21	S8
Figure S4, Table S4. BROMOscan® selectivity assay	S9
Table S5. Invitrogen Kinase selectivity assay	S10
Chemistry Experimentals	S12-S37
Molecular modeling methods	S-38
Molecular modeling coordinates for Compound 1 bound to CECR2	S39-S52
Supporting Information references	S53-54

Protein expression and purification methods

Production of bromodomain proteins was carried out as previously described¹. TR-FRET assay conditions have been reported previously.^{2,3}

Synthesis of biotinylated probes for TR-FRET assays. The synthesis and characterization of biotinylated probe molecules has been previously reported.²

Cell-based assay

The bromodomain chromatin-release (“dot”) assay has been described previously for the CBP bromodomain.⁴ Briefly, a cell line derived from U2OS, U2OS-C433, expressing a ZsGreen fluorescence tag fused to a nuclear localization signal sequence (MDPKKKRKVDPKKRKVDPKKKKRKV) followed by CECR2 bromodomain (M404–H515), was used to visualize the localization of the bromodomain. In the absence of target engagement, the fluorescence signal is seen in the nucleus and is diffuse. Addition of inhibitor results in the formation of large nuclear puncta (“dots”) that are quantified and converted to compound EC₅₀ values as previously described.⁴

Crystallography methods

Crystals of the CECR2 ligand complex were grown by vapor diffusion with a precipitant solution of 1.5 M lithium sulfate and 0.1 M Tris-HCl pH 8.5 combined with protein solution at a ratio of 4:3. Protein concentration was 21.5 mg/mL with final ligand concentration at 2 mM. Crystals grew after 3–4 weeks of incubation at 4 °C. Data were collected at the Advanced Photon Source (APS beamline: SER-CAT 22BM) at a wavelength of 1.00 Å. Crystals were dipped in a 1:1 mixture of paratone and paraffin oil prior to flash cooling in liquid nitrogen. The data were integrated and scaled to 2.7 Å resolution with HKL2000⁵ and determined to be of space group I222 (Table 1). The initial structure was determined by the molecular replacement method using PHASER⁶, using an internal bromodomain structure as a search

model. The model was adjusted using COOT⁷, and the final refinement was performed with BUSTER^{8,9} to an R_{free} value of 22.2% and included four protein molecules per asymmetric unit.

Table S1. Crystallographic data collection and refinement statistics for Compound 6 bound to CECR2 [PDB 5V84].

Data Collection	
Wavelength (Å)	1.0
Resolution range*	50.0 - 2.70 (2.8 - 2.7)
Space group	I222
Unit cell (a,b,c,α,β,γ)	101.18 116.49 132.93 90 90 90
Total reflections	133,846
Unique reflections	21,604 (2117)
Multiplicity	6.2 (6.2)
Completeness (%)	99 (100)
Mean I/sigma(I)	16.3 (2.4)
Wilson B-factor	72.8
R_{merge}	0.07 (0.52)
Refinement	
Resolution	43.8 – 2.7 (2.83 – 2.7)
Reflections used in refinement	21,595 (1,900)
$R_{\text{work}}/ R_{\text{free}}$ (%)	20.6/22.2 (24.4/25.7)
Number of non-hydrogen atoms	3,521
macromolecules	3,359
ligands	138
solvent	24
Protein residues	406
RMS(bonds)	0.010
RMS(angles)	0.96
Ramachandran favored (%)	97
Ramachandran allowed (%)	2.5
Ramachandran outliers (%)	0
Rotamer outliers (%)	6.4
Clashscore	13.70
Average B-factor	84.34
macromolecules	78.30
ligands	78.49
solvent	61.95
Number of TLS groups	16

*Statistics for the highest-resolution shell are shown in parentheses.




Figure S1. Comparison of the Compound 6 structure with Apo structure residues Phe459, Tyr520, Met506 in red. Compound 6 is shown as green sticks and H-bond interactions are represented as black dashes.

Table S2. TR-FRET assay data for compounds Tables 1 and 2 including standard deviations.

Compound	CECR2	BRD4(1)	BRD4(2)	BRD9	TAF1(2)
IC ₅₀ (uM)					
2	0.78 ± 0.3	>20	17.2 ± 0.7	>20	6.1 ± 0.6
3	0.50 ± 0.04	>20	19.2 ± 0.4	17.8 ± 2	8.4 ± 0.2
4	0.33 ± 0.06	>20	6.1 ± 0.5	11 ± 1	3.6 ± 0.5
5	0.50 ± 0.01	>20	>20	>20	16.1 ± 0.3
6	0.20 ± 0.02	>20	>20	3.5 ± 0.0	16.5 ± 0.4
7	0.19 ± 0.02	>20	>20	4.4 ± 0.1	11.9 ± 2

Compound	CECR2	BRD4(1)	BRD9	TAF1(2)
IC ₅₀ (uM)				
8	0.24 ± 0.1	>20	5 ± 0.3	2.1 ± 0.6
9	0.2 ± 0.06	>20	11.4 ± 0.3	3.4 ± 0.8
10	0.13 ± 0.02	>20	8.5 ± 0.2	2.8 ± 0.5
11	0.083 ± 0.02	>20	6.1 ± 0.7	1.8 ± 0.2
12	0.055 ± 0.004	>20	5.7 ± 0.8	2.8 ± 0.3
13	0.071 ± 0.01	>20	5.8 ± 1	2.7 ± 0.3
14	0.093 ± 0.02	>20	7.6 ± 0.7	5.1 ± 0.5
15	0.052 ± 0.001	>20	3.5 ± 0.2	3.3 ± 0.3
16	0.059 ± 0.002	>20	6.9 ± 1	3.4 ± 0.4
17	0.045 ± 0.02	>20	3.3 ± 0.3	2.5 ± 0.6
18	0.046 ± 0.001	>20	1.7 ± 0.2	2.4 ± 0.4
19	0.044 ± 0.02	>20	1.5 ± 0.2	2.5 ± 0.8
20	0.045 ± 0.01	>20	2.6 ± 0.4	2.6 ± 0.4
21	0.016 ± 0.002	>20	1.6 ± 0.1	1.4 ± 0.1




Figure S2. Displacement of a CECR2 ZsGreen fusion protein from chromatin. Control cells in DMSO in Figure S1A, and aggregate dots resulting from displacement highlighted in Figure S1B.




Figure S3. Representative dose-response curve for compound **21** in CECR2 dot assay.

Table S3. CECR2 dot assay data for 6 replicate experiments (A-F), measuring the percent activation observed at 10 concentrations for compound **21** ($EC_{50} = 370$ nM).

Conc (μM) of compd 21	Percent activation					
	A	B	C	D	E	F
40	100.1	96.2	99.9	88.0	100.0	101.4
20	111.0	106.9	97.6	91.8	102.2	107.1
10	97.7	89.6	87.6	92.3	106.5	
5	102.0	108.5	102.4	99.3	105.1	105.5
2.5	99.2	99.2	86.4	87.5	93.3	99.2
1.25	74.4	81.4	74.4	86.6	95.6	87.7
0.625	63.2	62.9	56.3	62.7	44.8	65.8
0.315	48.0	45.5	6.1	-1.9	-0.3	-0.4
0.16	9.7	10.6	-5.1	-7.7	-0.2	0.2
0.08	0.4	-0.4	0.1	-2.5	-0.3	0.7




Figure S4. BROMOscan data for GNE-886. K_d values are the average of 2 independent experiments.

Table S3. BROMOscan[®] bromodomain selectivity data for compound **21** (GNE-886) provided by DiscoverX Corp., Fremont, CA, USA, <http://www.discoverx.com>. This screen measured binding competition against immobilized ligands for 40 DNA-tagged bromodomains. Compound Kd values are an average of 2 independent experiments.

Target	GNE-886	Target	GNE-886	Target	GNE-886
Gene Symbol	Kd (nM)	BRD4(2)	>10000	FALZ	>10000
ATAD2A	>10000	BRD4(full-length,short-iso.)	>10000	GCN5L2	>10000
ATAD2B	>10000	BRD7	1100	PBRM1(2)	>10000
BAZ2A	>10000	BRD8(1)	>10000	PBRM1(5)	>10000
BAZ2B	>10000	BRD8(2)	>10000	PCAF	>10000
BRD1	>10000	BRD9	2000	SMARCA2	>10000
BRD2(1)	>10000	BRDT(1)	>10000	SMARCA4	>10000
BRD2(1,2)	>10000	BRDT(1,2)	>10000	TAF1(2)	620
BRD2(2)	5300	BRDT(2)	>10000	TAF1L(2)	2400
BRD3(1)	>10000	BRPF1	>10000	TRIM24(Bromo.)	>10000
BRD3(1,2)	>10000	BRPF3	>10000	TRIM24(PHD,Bromo.)	>10000
BRD3(2)	4900	CECR2	42	TRIM33(PHD,Bromo.)	>10000
BRD4(1)	>10000	CREBBP	>10000	WDR9(2)	>10000
BRD4(1,2)	>10000	EP300	>10000		


Table S4: Kinase selectivity data for Compound 21 (GNE-886). Invitrogen panel of 35 kinases, percent inhibition at 1.0 μ M.

Kinase	GNE-886 @1.0uM	Kinase	GNE-886 @1.0uM
AKT1	2.5	MAP4K4	6.5
Abl	9	MEK1	3.5
Aurora_B	1	MST3	3
CDK2/cyclinA	0.5	MYLK3(caMLCK)	1.5
CDK5/p25	-1.5	Mink1	10
CHK1	10.5	MuSK	1.5
CLK2	6.5	PIM1	2.5
CSF1R	6	PKA	1.5
DMPK	0.5	PLK1	-2
EphA1	3.5	RIPK2	-0.5
Flt3	2.5	RSK3	4.5
GSK3_beta	3.5	Ret	1
IRAK4	11.5	SIK2	0.5
InsR	3.5	Src	3
JAK1	-5	TGFBR1	3
JNK1_alpha1	9.5	TrkA	11.5
Lck	18.5	Yes	4
		p38_alpha(direct)	3


Chemistry Methods. All solvents and reagents were used as obtained. NMR analysis performed in a deuterated solvent with a Varian Avance 300-MHz or Bruker Avance 400- or 500-MHz NMR spectrometers, referenced to trimethylsilane (TMS). Chemical shifts are expressed as δ units using TMS as the external standard (in NMR description, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad peak). All coupling constants (J) are reported in Hertz. Mass spectra were measured with a Finnigan SSQ710C spectrometer using an ESI source coupled to a Waters 600MS high performance liquid chromatography (HPLC) system operating in reverse-phase mode with an X-bridge Phenyl column of dimensions 150 mm by 2.6 mm, with 5 μ m sized particles. Preparatory-scale silica gel chromatography was performed using medium-pressure liquid chromatography (MPLC) on a CombiFlash Companion (Teledyne ISCO) with RediSep normal phase silica gel (35–60 μ m) columns and UV detection at 254 nm. Reverse-phase (HPLC) was used to purify compounds as needed by elution from a Phenomenex Gemini-NX C18 column (20.2 x 50 mm, 5 μ m) as stationary phase using mobile phase indicated, and operating at a 35 mL/min flow rate on a Waters 3100 mass-directed prep instrument. Chiral separation was performed on a Thar 80 prep SFC with ChiralCel OD-H column (250 x 30 mm, 5 μ m) as stationary phase using mobile phase as indicated, and operating at a 40 mL/min flow rate. Chemical purities were >95% for all final compounds as assessed by LC/MS analysis. The following analytical methods were used to determine chemical purity of final compounds: 1) HPLC-Agilent 1200, water with 0.05% TFA, acetonitrile with 0.05% TFA (buffer B), Agilent SB-C18, 1.8 μ m, 2.1 x 30 mm, 25 °C, 3–95% buffer B in 8.5 min, 95% in 2.5 min, 400 μ L/min, 220 nm and 254 nm, equipped with Agilent quadrupole 6140, ESI positive, 90-1300 amu. 2) Chiral SFC, ChiralCel AD-H column, 150 x 4.6 mm, 5 μ m, CO₂ mobile phase

A, with methanol with 0.05% diethylamine (mobile phase buffer B), 40 °C, 40% buffer B 2.35 mL/min.

Scheme S1. Synthesis of carboxylic acid Intermediate 25.




Compound 23. methyl 7-oxo-1-(p-tolylsulfonyl)-6H-pyrrolo[2,3-c]pyridine-4-carboxylate




[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (5.0 g, 8.5 mmol) was added to a mixture of 4-bromo-1-(p-tolylsulfonyl)-6H-pyrrolo[2,3-c]pyridin-7-one¹ (10.0 g, 27.3 mmol), Et₃N (20.0 mL, 143.5 mmol) in methanol (1 L). After addition, the mixture was stirred under CO atmosphere (50 psi) at 80 °C for 24 h, at which time TLC (petroleum ether :ethyl acetate=1:1) showed the completion of the reaction. The resulting mixture was concentrated under reduced pressure and the residue was purified by flash column (petroleum ether : ethyl acetate=5:1 to 3:1) to give the title compound (Intermediate B) (7.5 g, 79.5% yield) as a brown solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.79 (s, 1 H), 8.03 (d, *J* = 3.6 Hz, 1 H), 7.88 (d, *J* = 8.4 Hz, 2 H), 7.80 (s, 1 H), 7.37 (d, *J* = 8.0 Hz, 2 H), 7.05 (d, *J* = 3.2 Hz, 1 H), 3.77 (s, 3 H), 2.33 (s, 3 H).

Compound 24. methyl 6-methyl-7-oxo-1-(p-tolylsulfonyl)pyrrolo[2,3-c]pyridine-4-carboxylate



Methyl iodide (18.1 g, 127.24 mmol) was added dropwise to a stirred solution of methyl 7-oxo-1-(p-tolylsulfonyl)-6H-pyrrolo[2,3-c]pyridine-4-carboxylate (11.6 g, 33.49 mmol) and Cs_2CO_3 (13.1 g, 40.18 mmol) in dioxane (230 mL). After addition, the resulting mixture was stirred at room temperature for 4 hr, at which time TLC indicated the reaction was completed. The solid was removed by filtration and the filtrate was concentrated. The residue was dissolved in ethyl acetate (250 mL) and washed with water (50 mL x 2). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to give the title compound (11.0 g, 91.1% yield) as a white solid. This crude was used into next step without further purification. LCMS m/z (M+H) 360.9.


Intermediate 25. 6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxylic acid



Sodium hydroxide (6.0 g, 150.0 mmol) was added in portions to a stirred solution of methyl 6-methyl-7-oxo-1-(p-tolylsulfonyl)pyrrolo[2,3-c]pyridine-4-carboxylate (12.0 g, 33.3 mmol) in methanol/water (260/30 mL). After addition, the mixture was stirred at 80 °C for 2 h, at which time LCMS indicated the reaction had gone to completion. After cooling, the mixture was


concentrated under reduced pressure. The residue was dissolved in water (30 mL) and the aqueous solution was acidified to pH 3-4 using 5 N hydrochloric acid. The resulting precipitate was collected by filtration, washed with water, and dried under reduced pressure to give the title compound (Intermediate C) (4.3 g, 67.2% yield) as a brown solid. This crude material was used in the next step without further treatment. LCMS m/z (M+H) 192.8.


Intermediate 26. 6-allyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxylic acid




Intermediate **26** was prepared in a similar fashion as Intermediate **25**, utilizing allyl bromide as alkylating agent and potassium carbonate as base, (4.04 g, 91% yield over 2 steps). LCMS m/z (M+H) 240.1, 219.3

Scheme S2. Synthesis of carboxylic acid Intermediate **33**.



Compound 28. 5-bromo-2-methoxy-3-nitropyridine


Sodium methoxide (17.2 g, 318.4 mmol) was added to a stirred solution of 5-bromo-2-chloro-3-nitropyridine (15.0 g, 64.2 mmol) in methanol (125 mL). After addition, the reaction mixture was heated at reflux for 2 h. The mixture was concentrated under reduced pressure, and the residue was diluted with water (200 mL). The resulting precipitate was collected by filtration, washed with water, and dried under reduced pressure to give the title compound (12.0 g, 81.5% yield) as a brown solid. ^1H NMR (400MHz, CDCl_3): δ 8.43 (d, J = 2.4 Hz, 1 H), 8.38 (d, J = 2.0 Hz, 1 H), 4.09 (s, 3 H).

Compound 29. 4-bromo-7-methoxy-2-methyl-1H-pyrrolo[2,3-c]pyridine

Isopropenyl magnesium bromide (0.5 M in THF, 105.0 mL, 55.0 mmol) was added dropwise to a stirred and cooled (-78°C) solution of 5-bromo-2-methoxy-3-nitropyridine (4.0 g, 17.1 mmol) in THF (40 mL). After addition, the resulting mixture was allowed to warm to room temperature gradually and stirred for an additional 3 h. The reaction mixture was quenched by addition of 1 M aqueous ammonium chloride (150 mL), and then extracted with ethyl acetate (3 x 100 mL). The combined organic extracts were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether : ethyl acetate


= 10:1) to give the title compound (1.65 g, 39.9% yield) as brown oil. LCMS m/z (M+H) 240.1, 242.1.

Compound 30. 4-bromo-2-methyl-1,6-dihydropyrrolo[2,3-c]pyridin-7-one



Hydrogen bromide (40% aqueous, 20 mL) was added to a solution of 4-bromo-7-methoxy-2-methyl-1H-pyrrolo[2,3-c]pyridine (1.65 g, 6.8 mmol) in ethanol (10 mL). After addition, the reaction mixture was heated at 90°C for 15 h, at which time TLC indicated the reaction had gone to completion. The mixture was cooled to 0 °C and the resulting solid was collected by filtration. This solid was washed with water and dried to give title compound (Intermediate B, 0.9 g, 57.9% yield) as a brown solid. ^1H NMR (400MHz, DMSO- d_6): δ 12.06 (s, 1 H), 11.00 (s, 1 H), 7.03 (s, 1 H), 5.97 (s, 1 H), 2.29 (s, 3 H). LCMS m/z (M+H) 226.8, 228.8


Compound 31. Methyl 2-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxylate



A mixture of 4-bromo-2-methyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one (Intermediate E) (9.0 g, 39.6 mmol), Et₃N (15 ml, 107.6 mmol) and Pd(dppf)Cl₂ (2.4 g, 3.3 mmol) in methanol (1.0 L) was heated at 80 °C under CO atmosphere (50 psi) for 18 h, at which time LCMS showed the completion of the reaction. After cooled, the solvent was evaporated under reduced pressure.

The residue was diluted with water (150 mL) and the resulting precipitate was collected by filtration. The solid was washed with water (10 mL x 2), isopropanol (10 mL x 2) and dried to give the title compound (5.0 g, 61% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.94 (s, 1 H), 11.32 (s, 1 H), 7.63 (d, J = 6.4, 1 H), 6.44 (s, 1 H), 3.76 (s, 3 H), 2.30 (s, 3 H). LCMS m/z (M+H) 207.0.


Intermediate 33. 6-allyl-2-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxylic acid



To a solution of methyl 2-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxylate (10.0 g, 48.5 mmol) in DMF (100 mL) was added K_2CO_3 (20.1 g, 145.0 mmol) and allyl bromide (5.9 g, 48.5 mmol). After addition, the mixture was stirred at ambient temperature for 12 h, at which time LCMS showed the completion of the reaction. The reaction mixture was diluted with ice-water (200 mL). The resulting precipitate was collected by filtration, washed with water and dried.

A suspension of the above crude product in methanol (150 mL) and was added KOH (10.9 g, 194 mmol) in water (50 mL). The mixture was heated at 50 °C for 4 h, at which time LCMS showed the completion of the reaction. Methanol was evaporated under reduced pressure, and the aqueous solution was acidified by adding 2M HCl to pH 2. The resulting precipitate was collected by filtration and dried to give the title compound (10.2 g, 91% yield) as a grey solid. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 12.51 (s, 1H), 12.04-11.89 (m, 1H), 7.93 (s, 1H), 6.48 (dd, J = 2.4 Hz, 1H), 5.98 (ddt, J = 17.2, 10.6, 5.4 Hz, 1H), 5.23 – 5.13 (m, 1H), 5.07 (ddt, J = 17.1, 1.7, 1.7 Hz, 1H), 4.68 (dt, J = 5.7, 1.7 Hz, 2H), 2.34 (s, 3H). LCMS m/z (M+H) 233.3

Compound 1. 6-methyl-N-(1-methyl-4-piperidyl)-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide




To a solution of 6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxylic acid (30 mg, 0.156 mmol, 1.0 equiv) in DMF (1.0 mL) was added N1,N1-dimethylcyclohexane-1,4-diamine dihydrochloride (18.7 mg, 0.187 mmol, 1.2 equiv), HATU (78 mg, 0.203 mmol, 1.3 equiv) and N,N-diisopropylethylamine (110 uL, 0.624 mmol, 4.0 equiv). Reaction was stirred at room temperature for 16 hr. The reaction mixture was concentrated under vacuum and the crude product was purified by Prep-HPLC (Column, Gemini C18 100x30 mm; mobile phase, CH₃CN:NH₄OH/H₂O (10 mmol/L) = 5%-85%, 10min; flow rate, 70 mL/min; Detector, UV 254 nm) to give 21.7 mg (44%) of N-[4-(dimethylamino)cyclohexyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide as an off white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 12.03 (s, 1H), 7.81 (s, 1H), 7.76 (d, *J* = 7.6 Hz, 1H), 7.30 (s, 1H), 6.68 (dd, *J* = 2.9, 1.2 Hz, 1H), 3.77 – 3.63 (m, 1H), 3.55 (s, 3H), 2.75 (d, *J* = 11.7 Hz, 2H), 2.16 (s, 3H), 2.00 – 1.89 (m, 2H), 1.78 (d, *J* = 12.5 Hz, 2H), 1.62 – 1.47 (m, 2H). LCMS *m/z* (M+H) 289

The following compounds were prepared in a similar manner as compound 1.


Compound 2. N,6-dimethyl-N-(1-methyl-4-piperidyl)-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide, 13 mg (30%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.11 (s, 1H), 7.36 (s, 1H), 7.31 (d, *J* = 2.6 Hz, 1H), 6.18 (d, *J* = 2.7 Hz, 1H), 3.95 (s, 1H), 3.52 (s, 3H), 2.84 – 2.76 (m, 5H), 2.12 (s, 3H), 1.85 – 1.73 (m, 4H), 1.61 – 1.54 (m, 2H). LCMS *m/z* (M+H) 303.2

Compound 3. N-(1-isopropyl-4-piperidyl)-N,6-dimethyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide, 21 mg (41% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.11 (s, 1H), 7.36 (s, 1H), 7.32 (t, *J* = 2.7 Hz, 1H), 6.21 – 6.15 (m, 1H), 3.93 (s, 1H), 3.52 (s, 3H), 2.85 – 2.77 (m, 5H), 2.66 (p, *J* = 6.6 Hz, 1H), 2.10 – 2.02 (m, 2H), 1.81 – 1.66 (m, 2H), 1.65 – 1.57 (m, 2H), 0.92 (d, *J* = 6.5 Hz, 6H). LCMS *m/z* (M+H) 331.2

Compound 4. N,6-dimethyl-7-oxo-N-[1-(1-phenylethyl)-4-piperidyl]-1H-pyrrolo[2,3-c]pyridine-4-carboxamide




Step 1: N-methyl-1-(1-phenylethyl)piperidin-4-amine dihydrochloride



To a 40 mL vial was added 1-bromoethylbenzene (475 mg, 2.6 mmol) tert-butyl N-methyl-N-(4-piperidyl)carbamate (500 mg, 2.3 mmol), acetonitrile (4 mL), and *N,N*-diisopropylethylamine (1.2 mL 7.0 mmol). The reaction was capped and shaken at 80°C overnight. The reaction was cooled to room temperature, then extracted with ethyl acetate/water. The organic phase was concentrated under reduced pressure. The crude product was then taken up in 10 mL methanol, and 10 mL of 4M HCl in dioxane was added. The reaction was stirred for 1h. The resulting precipitate was collected by filtration, and washed 2x with ethyl acetate, yielding desired product as a white solid (510 mg, 75% over two steps). LCMS *m/z* (M+H) 219.3


Step 2: N,6-dimethyl-7-oxo-N-[1-(1-phenylethyl)-4-piperidyl]-1H-pyrrolo[2,3-c]pyridine-4-carboxamide



Compound **4** was prepared in a similar manner to compound 1, utilizing Int **25** and *N*-methyl-1-(1-phenylethyl)piperidin-4-amine dihydrochloride from step 1, 71 mg (53% yield). LCMS *m/z* (M+H) 393.3

Compound **5** was prepared in a similar manner to compound 1, utilizing Int **26** and *N*-methyl-1-(1-phenylethyl)piperidin-4-amine dihydrochloride from step 1, 87 mg (60% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.41 – 7.12 (m, 7H), 6.16 (d, *J* = 2.7 Hz, 1H), 3.51 (s, 3H), 3.48 – 3.37 (m, 1H), 3.09 – 2.59 (m, 4H), 1.94 – 1.59 (m, 6H), 1.33 – 1.23 (m, 3H). LCMS *m/z* (M+H) 419.4

Compounds **6** & **7**.




The racemic mixture was prepared in a similar manner to compound 1, utilizing Int **33** and *N*-methyl-1-(1-phenylethyl)piperidin-4-amine dihydrochloride from step 1. The racemate was then separated by SFC (SFC80; Chiralpak OD 250 X 30 mm I.D., 5μm; Supercritical CO₂ / MeOH+NH₃.H₂O= 60/40; 40 ml/min, 100 bars, 40 °C) to give yield purified enantiomers:

Compound 6 (Peak 1): 6-allyl-N,2-dimethyl-7-oxo-N-(1-(1-phenylethyl)piperidin-4-yl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (19.2 mg, 7%) as white solid. ¹H NMR (400 MHz, 340K, DMSO-*d*₆) δ 11.67 (s, 1H), 7.35 – 7.25 (m, 4H), 7.25 – 7.17 (m, 1H), 7.12 (s, 1H), 6.01 – 5.86 (m, 2H), 5.11 (ddt, *J* = 10.3, 1.5, 1.5 Hz, 1H), 5.02 (ddt, *J* = 17.1, 1.6, 1.6 Hz, 1H), 4.58 (dt, *J* = 5.5, 1.6 Hz, 2H), 3.91 – 3.86 (m, 1H), 3.52 – 3.47 (m, 1H), 3.05 – 2.97 (m, 1H), 2.86 – 2.77 (m, 4H), 2.30 (s, 3H), 2.00 – 1.66 (m, 4H), 1.65 – 1.50 (m, 2H), 1.28 (d, *J* = 6.8 Hz, 3H). LCMS *m/z* (M+H): 433. Retention time, 6.77 minutes. Enantiomeric ratio: 97:3.


Compound 7 (Peak 2): 6-allyl-N,2-dimethyl-7-oxo-N-(1-(1-phenylethyl)piperidin-4-yl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (37.4 mg, 13%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.69 (s, 1H), 7.34 – 7.26 (m, 4H), 7.25 – 7.17 (m, 1H), 7.12 (s, 1H), 6.00 – 5.87 (m, 2H), 5.10 (ddt, *J* = 10.3, 1.6, 1.6 Hz, 1H), 5.02 (ddt, *J* = 17.2, 1.7, 1.7 Hz, 1H), 4.58 (dd, *J* = 5.6, 1.8 Hz, 2H), 3.90 – 3.85 (m, 1H), 3.50 – 3.41 (m, 1H), 3.04 – 2.94 (m, 1H), 2.90 – 2.75 (m, 4H), 2.31 (s, 3H), 1.95 – 1.65 (m, 4H), 1.65 – 1.48 (m, 2H), 1.27 (d, *J* = 6.8 Hz, 3H). LCMS [M+H]: 433. Retention time 12.25 minutes. Enantiomeric ratio >99:1.

Compound 8: 6-allyl-N-methyl-7-oxo-N-(1-pyrimidin-4-yl-4-piperidyl)-1H-pyrrolo[2,3-c]pyridine-4-carboxamide



Step 1:


tert-butyl methyl(1-(pyrimidin-4-yl)piperidin-4-yl)carbamate



A mixture of tert-butyl methyl(piperidin-4-yl)carbamate (500 mg, 2.3 mmol), cesium carbonate (836 mg, 2.6 mmol) and 4-chloropyrimidine (294 mg, 2.6 mmol) in DMF (10 mL) was heated at 80 °C for 3 h, at which time LCMS indicated full conversion of starting material. The reaction mixture was poured into ice water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic extracts were dried over sodium sulfate and concentrated under reduced pressure to give the title compound (450 mg, 66.0% yield) as a yellow solid. This crude material was used in the next step without further purification.

Step 2:


N-methyl-1-(pyrimidin-4-yl)piperidin-4-amine hydrochloride



To a cooled (0 °C) solution of tert-butyl methyl(1-(pyrimidin-4-yl)piperidin-4-yl)carbamate (300 mg, 1.0 mmol) in ethyl acetate (50 mL) was added hydrogen chloride (2M in ethyl acetate, 10 mL). After addition, the reaction mixture was stirred at 25 °C for 3 h. The solvent was evaporated under reduced pressure to give the crude title compound (165 mg, 72% yield) as a yellow solid.

Step 3:

N,6-dimethyl-7-oxo-N-(1-pyrimidin-4-yl-4-piperidyl)-1H-pyrrolo[2,3-c]pyridine-4-carboxamide



A mixture of Intermediate **26** (50 mg, 0.23 mmol), triethylamine (93 mg, 0.92 mmol), HATU (94 mg, 0.24 mmol) and 1-(pyrimidin-4-yl)piperidin-4-amine hydrochloride (62 mg, 0.27 mmol) in DMF (1 mL) was stirred at 25 °C overnight. The reaction was then diluted with DCM, washed with water, and the organic phase concentrated under reduced pressure. The residue was purified by preparative HPLC, acetonitrile : water (10 mM ammonia) : 32%-62%, to give the title compound. 6-allyl-N-methyl-7-oxo-N-(1-pyrimidin-4-yl-4-piperidyl)-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (32 mg, 35% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 12.14 (s, 1H), 8.47 (d, *J* = 1.2 Hz, 1H), 8.15 (d, *J* = 6.2 Hz, 1H), 7.43 – 7.25 (m, 2H), 6.85 (dd, *J* = 6.4, 1.3 Hz, 1H), 6.24

(t, $J = 2.3$ Hz, 1H), 5.99 (ddt, $J = 17.2, 10.5, 5.3$ Hz, 1H), 5.17 (ddt, $J = 10.3, 1.4, 1.4$ Hz, 1H), 5.13 – 5.01 (m, 1H), 4.72 – 4.58 (m, 2H), 4.51 (d, $J = 13.1$ Hz, 2H), 4.33 (s, 1H), 2.79 (s, 5H), 1.72 (td, $J = 11.4, 10.2, 3.8$ Hz, 4H). LCMS m/z (M+H) 393.2

Compound 9: 6-allyl-N-methyl-7-oxo-N-[1-[6-(trifluoromethyl)pyrimidin-4-yl]-4-piperidyl]-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (49% yield). ^1H NMR (400 MHz, DMSO- d_6) δ 12.16 (s, 1H), 8.61 (d, $J = 1.1$ Hz, 1H), 7.38 – 7.27 (m, 3H), 6.25 (d, $J = 2.7$ Hz, 1H), 6.06 – 5.92 (m, 1H), 5.22 – 5.13 (m, 1H), 5.12 – 5.02 (m, 1H), 4.68 – 4.60 (m, 2H), 4.41 – 4.36 (m, 1H), 3.35 – 3.23 (m, 2H), 2.96 (s, 2H), 2.79 (s, 3H), 1.79 – 1.72 (m, 4H). LCMS m/z (M+H) 461.2

Compound 10: 6-allyl-N-[1-(6-methoxypyrimidin-4-yl)-4-piperidyl]-N-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (31% yield). ^1H NMR (400 MHz, DMSO- d_6) δ 12.15 (s, 1H), 8.23 (d, $J = 0.8$ Hz, 1H), 7.34 (d, $J = 2.8$ Hz, 1H), 7.30 (s, 1H), 6.24 (d, $J = 2.7$ Hz, 1H), 6.10 (d, $J = 0.9$ Hz, 1H), 6.06 – 5.91 (m, 1H), 5.21 – 5.12 (m, 1H), 5.12 – 5.01 (m, 1H), 4.64 (dt, $J = 5.5, 1.5$ Hz, 2H), 4.45 (d, $J = 13.1$ Hz, 2H), 4.30 (s, 1H), 3.81 (s, 3H), 3.37 – 3.25 (m, 1H), 2.78 (s, 5H), 1.74 – 1.62 (m, 4H). LCMS m/z (M+H) 423.2.

Compound 11: 6-allyl-N-[1-(6-cyclopropylpyrimidin-4-yl)-4-piperidyl]-N-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (34% yield). ^1H NMR (400 MHz, DMSO- d_6) δ 12.16 (s, 1H), 8.30 (d, $J = 1.0$ Hz, 1H), 7.38 – 7.28 (m, 2H), 6.79 (d, $J = 1.2$ Hz, 1H), 6.24 (dd, $J = 2.9, 1.4$ Hz, 1H), 6.06 – 5.91 (m, 1H), 5.21 – 5.13 (m, 1H), 5.12 – 5.01 (m, 1H), 4.67 – 4.60 (m, 2H), 4.51 (d, $J = 13.2$ Hz, 2H), 4.44 – 4.18 (m, 1H), 3.37 – 3.23 (m, 22H), 2.91 – 2.72 (m, 5H), 1.95 – 1.84 (m, 1H), 1.76 – 1.63 (m, 4H), 0.98 – 0.84 (m, 4H). LCMS m/z (M+H) 433.2

Compound 12: 6-allyl-N-[1-(6-tert-butylpyrimidin-4-yl)-4-piperidyl]-N-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (11% yield). ^1H NMR (400 MHz, DMSO- d_6) δ 12.15 (s, 1H), 8.14 (d, $J = 6.1$ Hz, 1H), 7.32 (d, $J = 19.9$ Hz, 2H), 6.63 (d, $J = 6.2$ Hz, 1H), 6.24 (d, $J = 2.8$


Hz, 1H), 5.99 (ddt, $J = 17.0, 10.4, 5.4$ Hz, 1H), 5.17 (ddt, $J = 10.2, 1.3, 1.3$ Hz, 1H), 5.07 (ddt, $J = 17.3, 1.6, 1.6$ Hz, 1H), 4.64 (dt, $J = 5.8, 1.6$ Hz, 2H), 4.55 (s, 1H), 2.79 (s, 5H), 1.73 (td, $J = 11.4, 10.2, 4.0$ Hz, 4H), 1.27 (s, 9H). LCMS m/z (M+H) 449.2G0

Compound 13: 6-allyl-N-[1-(6-methoxy-2-methyl-pyrimidin-4-yl)-4-piperidyl]-N-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (32 % yield). ^1H NMR (400 MHz, DMSO- d_6) δ 12.15 (s, 1H), 7.37 – 7.27 (m, 2H), 6.23 (d, $J = 2.7$ Hz, 1H), 6.06 – 5.88 (m, 2H), 5.17 (d, $J = 10.2$ Hz, 1H), 5.11 – 5.02 (m, 1H), 4.63 (d, $J = 5.4$ Hz, 2H), 4.45 (d, $J = 13.0$ Hz, 2H), 4.29 (s, 0H), 3.79 (s, 3H), 2.93 – 2.68 (m, 5H), 2.31 (s, 3H), 1.69 (t, $J = 5.9$ Hz, 4H). LCMS m/z (M+H) 437.2

Compound 14: 6-allyl-N-[1-(2,6-dimethylpyrimidin-4-yl)-4-piperidyl]-N-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (36% yield). ^1H NMR (400 MHz, DMSO- d_6) δ 12.16 (s, 1H), 7.38 – 7.27 (m, 2H), 6.53 (s, 1H), 6.28 – 6.21 (m, 1H), 6.06 – 5.91 (m, 1H), 5.21 – 5.13 (m, 1H), 5.12 – 5.01 (m, 1H), 4.64 (dt, $J = 5.4, 1.6$ Hz, 2H), 4.51 (d, $J = 13.1$ Hz, 2H), 4.31 (s, 1H), 2.81 – 2.76 (m, 5H), 2.31 (s, 3H), 2.20 (s, 3H), 1.75 – 1.61 (m, 4H). LCMS m/z (M+H) 421.2


Compound 15: 6-allyl-N-[1-(6-cyclopropyl-2-methyl-pyrimidin-4-yl)-4-piperidyl]-N-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (11%). ^1H NMR (400 MHz, DMSO- d_6) δ 12.15 (s, 1H), 7.38 – 7.27 (m, 2H), 6.57 (s, 1H), 6.24 (d, $J = 2.6$ Hz, 1H), 5.99 (ddt, $J = 15.9, 10.3, 5.3$ Hz, 1H), 5.17 (d, $J = 10.2$ Hz, 1H), 5.07 (d, $J = 17.2$ Hz, 1H), 4.64 (d, $J = 5.4$ Hz, 2H), 4.51 (d, $J = 13.0$ Hz, 2H), 4.31 (s, 1H), 2.78 (s, 5H), 2.27 (s, 3H), 1.85 (tt, $J = 8.7, 5.1$ Hz, 1H), 1.68 (d, $J = 18.8$ Hz, 4H), 0.95 – 0.80 (m, 4H). LCMS m/z (M+H) 447.2

Compound 16: 6-allyl-N-methyl-7-oxo-N-[1-(6-pyrazol-1-ylpyrimidin-4-yl)-4-piperidyl]-1H-pyrrolo[2,3-c]pyridine-4-carboxamide



Step 1

tert-butyl (1-(6-chloropyrimidin-4-yl)piperidin-4-yl)(methyl)carbamate




To a solution of 4,6-dichloropyrimidine (5.2 g, 35.00 mmol) in DMF (100 mL) were added *tert*-butyl methyl(piperidin-4-yl)carbamate (5.0 g, 23.33 mmol) and cesium carbonate (15.2 g, 46.66 mmol). After addition, the reaction mixture was heated at 80 °C for 16 h, at which time LCMS indicated the reaction had gone to completion. The solution was poured into ice water, and

extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel chromatography column (Hexanes/ethyl acetate = 5:1) to give the title compound (7.0 g, 92% yield) as a colorless oil.

Step 2


1-(6-chloropyrimidin-4-yl)-N-methylpiperidin-4-amine hydrochloride



To a solution of *tert*-butyl (1-(6-chloropyrimidin-4-yl)piperidin-4-yl)(methyl) carbamate (7.0 g, 21.42 mmol) in ethyl acetate (25 mL) was added a solution of hydrogen chloride (2 in ethyl acetate, 10 mL). After addition, the mixture was stirred at room temperature for 3 h, at which time LCMS indicated the reaction had gone to completion. The solution was concentrated under reduced pressure to give the crude title compound (4.5 g, 80% yield) as a yellow oil.

Step 3


tert-butyl (1-(6-(1*H*-pyrazol-1-yl)pyrimidin-4-yl)piperidin-4-yl)(methyl)carbamate



To a solution of *tert*-butyl (1-(6-chloropyrimidin-4-yl)piperidin-4-yl)(methyl) carbamate (600 mg, 1.84 mmol) in DMF (10 mL) was added 1*H*-pyrazole (150 mg, 2.20 mmol) and cesium carbonate (1.2 g, 3.67 mmol). After addition, the reaction mixture was heated at 80 °C for 12 h, at which time LCMS indicated the reaction had gone to completion. After cooled, the solid was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (50 mL), washed with water (2 x 30 mL), dried over sodium sulfate and concentrated to give the crude title compound (500 mg, 76 % yield) as a yellow solid.

Step 4


1-(6-(1*H*-pyrazol-1-yl)pyrimidin-4-yl)-*N*-methylpiperidin-4-amine hydrochloride



To a solution of *tert*-butyl (1-(6-(1*H*-pyrazol-1-yl)pyrimidin-4-yl)piperidin-4-yl)(methyl) carbamate (500 mg, 1.39 mmol) in ethyl acetate (10 mL) was added hydrogen chloride (2M in ethyl acetate, 10 mL) at 0 °C. After addition, the mixture was stirred at ambient temperature for 2 h, at which time LCMS indicated the reaction had gone to completion. The solution was concentrated under reduced pressure to give the crude title compound (400 mg, 97% yield) as a white solid.

Step 5


6-allyl-*N*-methyl-7-oxo-*N*-[1-(6-pyrazol-1-ylpyrimidin-4-yl)-4-piperidyl]-1*H*-pyrrolo[2,3-*c*]pyridine-4-carboxamide



To a solution of 1-(6-(1*H*-pyrazol-1-yl)pyrimidin-4-yl)-*N*-methylpiperidin-4-amine hydrochloride (216 mg, 0.73 mmol) in DMF (4 mL) was added 6-allyl-7-oxo-6,7-dihydro-1*H*-pyrrolo[2,3-*c*]pyridine-4-carboxylic acid (80 mg, 0.37 mmol), *N*-ethyl-*N*-isopropylpropan-2-amine (142 mg, 1.1 mmol) and HATU (181 mg, 0.48 mmol). After addition, the mixture was stirred at ambient temperature for 1.5 h, at which time LCMS indicated that the reaction had gone to completion. The solvent was removed under reduce pressure. The residue was dissolved in ethyl acetate (20 mL), washed with brine (2 x 15 mL) and concentrated. The crude product was purified by reverse phase chromatography (acetonitrile 40% / 0.1% NH₄OH in water) to


give the title compound (12.8 mg, 8% yield) as a yellow solid. ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ 12.19 (s, 1 H), 8.68 (s, 1 H), 8.49 (s, 1 H), 7.91 (s, 1 H), 7.34 (d, $J = 11.6$ Hz, 2 H), 7.24 (s, 1 H), 6.63 (s, 1 H), 6.24 (s, 1 H), 5.99-5.94 (m, 1 H), 5.16 (d, $J = 10.0$ Hz, 1 H), 5.06 (d, $J = 17.2$ Hz, 1 H), 4.64-4.40 (m, 5 H), 3.03 (s, 2 H), 2.78 (s, 3 H), 1.79 (s, 4 H). LCMS m/z (M+H) 459.1.

Compound 17: 6-allyl-N-(1-(6-(furan-2-yl)pyrimidin-4-yl)piperidin-4-yl)-N-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxamide



Step 1:


1-(6-chloropyrimidin-4-yl)-N-methylpiperidin-4-amine hydrochloride



To a solution of *tert*-butyl (1-(6-chloropyrimidin-4-yl)piperidin-4-yl)(methyl)carbamate (7.0 g, 21.5 mmol) in ethyl acetate (50 mL) was added hydrogen chloride (2M in ethyl acetate, 50 mL). The reaction mixture was stirred at ambient temperature for 3 hours and then concentrated under reduced pressure to give the crude title compound as hydrogen chloride salt (5.5 g, 98%). This material was used directly in the next step without purification.

Step 2:

6-allyl-N-(1-(6-chloropyrimidin-4-yl)piperidin-4-yl)-N-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxamide




To a solution of 6-allyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxylic acid (2.8 g, 12.8 mmol), HATU (5.9 g, 15.4 mmol) and triethylamine (3.9 g, 38.5 mmol) in DMF (100 mL) was added 1-(6-chloropyrimidin-4-yl)-N-methylpiperidin-4-amine hydrochloride (4.4 g, 16.7 mmol). The mixture was stirred at 20 °C for 16 hours. The solution was poured into water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were

concentrated under reduced pressure and the residue was purified by silica gel chromatography (Hexanes/ethyl acetate=1:1) to give the title compound (2.8 g, 51%) as a yellow solid.

Step 3:


6-allyl-N-(1-(6-(furan-2-yl)pyrimidin-4-yl)piperidin-4-yl)-N-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxamide




To a solution of 6-allyl-N-(1-(6-chloropyrimidin-4-yl)piperidin-4-yl)-N-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (100 mg, 0.23 mmol) in dioxane / water (2.5/0.5 mL) was added furan-2-ylboronic acid (39 mg, 0.35 mmol), cesium carbonate (153 mg, 0.47 mmol) and Pd(dppf)Cl₂ (17 mg, 0.02 mmol). The mixture was stirred at 85 °C for 30 min by microwave under N₂. After cooled, the organic solution was concentrated under reduced pressure and the residue was purified by preparative HPLC (acetonitrile 20-50% / 0.1% NH₄OH in water) to give 6-allyl-N-(1-(6-(furan-2-yl)pyrimidin-4-yl)piperidin-4-yl)-N-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (16.9 mg, 16%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.19 (br. s, 1H), 8.47 (s, 1 H), 7.88 (s, 1H), 7.36 – 7.32 (m, 2 H), 7.20

– 7.19 (m, 1 H), 7.05 (s, 1 H), 6.68 – 6.66 (m, 1H), 6.25 – 6.24 (m, 1H), 6.00 – 5.98 (m, 1 H), 5.18 – 5.15 (m, 1 H), 5.09 – 5.04 (m, 1 H), 4.65 – 4.50 (m, 4 H), 4.37 – 4.33 (m, 1H), 2.94 – 2.90 (m, 2 H), 2.79 (s, 3H), 1.78 – 1.73 (m, 4H). LCMS m/z (M+H) 459.1

Compound 18: 6-allyl-N-methyl-N-[1-[6-(o-tolyl)pyrimidin-4-yl]-4-piperidyl]-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide



Step 1: N-methyl-1-(6-o-tolylpyrimidin-4-yl)piperidin-4-amine dihydrochloride




To an 8 mL vial was added tert-butyl N-[1-(6-chloropyrimidin-4-yl)-4-piperidyl]-N-methylcarbamate (200 mg, 0.61 mmol), o-tolylboronic acid (166 mg, 1.22 mmol), XPhos (0.05 equiv.,

15 mg 0.03 mmol) XPhos Precatalyst (26 mg, 0.03 mmol), 1,4-dioxane (2 mL), and potassium phosphate tribasic 2M in water (0.92 mL, 1.836 mmol, 2.0 mol/L). The reaction was capped and shaken at 90°C for 1h. The reaction was cooled to room temperature then diluted with DCM and washed with water. The organic was then concentrated under reduced pressure. LCMS m/z (M+H) 383.3

The crude was taken up with 1 mL DCM, and 1 mL trifluoroacetic acid was added. The reaction was capped and shaken at room temperature for 1h, and was then concentrated under reduced pressure and carried directly on to the amide coupling step. LCMS m/z (M+H) 283.3

Step 2: 6-allyl-N-methyl-N-[1-[6-(o-tolyl)pyrimidin-4-yl]-4-piperidyl]-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide



The amide was prepared in a similar manner as Compound **1**. 6-allyl-N-methyl-N-[1-[6-(o-tolyl)pyrimidin-4-yl]-4-piperidyl]-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (156 mg, 54 % yield). ^1H NMR (400 MHz, DMSO- d_6) δ 12.15 (s, 1H), 8.55 (d, J = 1.1 Hz, 1H), 7.42 – 7.22 (m, 6H), 6.90 (d, J = 1.3 Hz, 1H), 6.25 (d, J = 2.6 Hz, 1H), 5.99 (ddt, J = 17.0, 10.5, 5.4 Hz, 1H), 5.17 (ddt, J = 10.3, 1.4, 1.4 Hz, 1H), 5.07 (ddt, J = 17.2, 1.6, 1.6 Hz, 1H), 4.64 (dt, J = 5.6, 1.6

Hz, 3H), 4.34 (s, 1H), 2.88 (s, 1H), 2.80 (s, 3H), 2.34 (s, 3H), 1.75 (t, $J = 6.5$ Hz, 4H). LCMS m/z (M+H) 483.2

Compounds **19-20** were prepared in a manner similar to Compound 13

Compound 19: 6-allyl-N-(1-(6-(2-fluorophenyl)pyrimidin-4-yl)piperidin-4-yl)-N-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (22 mg, 16% yield). ^1H NMR (400 MHz, CD_3OD): δ 8.74 (s, 1 H), 7.79-7.70 (m, 2 H), 7.45 – 7.36 (m, 5 H), 6.39 (s, 1 H), 6.08 – 6.00 (m, 1 H), 5.37 – 5.33 (m, 1 H), 5.25 – 5.21 (m, 2H), 4.73 - 4.74 (m, 2 H), 4.50 – 4.47 (m, 2 H), 3.36-3.34 (m, 1 H), 2.96 - 2.90 (m, 4 H), 2.20 - 1.99 (m, 4 H). LCMS m/z (M+H) 487

Compound 20: 6-allyl-N-(1-(6-(2-methoxyphenyl)pyrimidin-4-yl)piperidin-4-yl)-N-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-4-carboxamide (20 mg, 17% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 12.19 (br. s, 1H), 8.56 (s, 1 H), 7.78 – 7.75 (m, 1 H), 7.42 – 7.40 (m, 1 H), 7.38 - 7.36 (m, 1 H), 7.30 (s, 1 H), 7.25 (s, 1H), 7.15 – 7.13 (m, 1H), 7.06 – 7.04 (m, 1H), 6.25 – 6.24 (m, 1 H), 5.99 – 5.95 (m, 1 H), 5.18 – 5.15 (m, 1 H), 5.08 – 5.06 (m, 1H), 5.04 – 5.03 (m, 2 H), 4.55 – 4.48 (m, 2 H), 4.35 – 4.30 (m, 1H), 3.84 (s, 3H), 2.96 – 2.90 (m, 2 H), 2.50 (s, 3H), 1.75 – 1.69 (m, 4H). LCMS m/z (M+H) 499

Compound 21: 6-allyl-N-[1-[6-(3-methoxyphenyl)pyrimidin-4-yl]-4-piperidyl]-N-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-4-carboxamide. Compound **21** was prepared in a similar manner to Compound **8**, starting from 4-chloro-6-(3-methoxyphenyl)pyrimidine. (165 mg, 33% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.88 (s, 1H), 8.55 (d, $J = 1.1$ Hz, 1H), 7.73 – 7.64 (m, 2H), 7.38 (t, $J = 7.9$ Hz, 1H), 7.30 (d, $J = 2.8$ Hz, 1H), 7.27 – 7.21 (m, 2H), 7.03 (dd, $J = 8.0, 2.6$ Hz, 1H), 6.24 (d, $J = 2.8$ Hz, 1H), 5.99 (ddt, $J = 17.2, 10.7, 5.5$ Hz, 1H), 5.18 (ddt, $J = 10.3, 1.5, 1.5$ Hz, 1H), 5.12 (ddt, $J = 17.2, 1.7, 1.7$ Hz, 1H), 4.70 – 4.58 (m, 4H), 4.35 (p, $J = 8.5$ Hz, 1H),

3.83 (s, 3H), 2.96 – 2.84 (m, 2H), 2.81 (s, 3H), 1.79 (td, $J = 9.4, 8.3, 4.2$ Hz, 4H). ^{13}C NMR (101 MHz, DMSO- δ_6 , 360 K) δ 167.98, 162.60, 162.33, 160.26, 158.42, 154.17, 139.69, 134.73, 129.99, 128.60, 127.99, 127.85, 123.47, 119.75, 117.43, 116.30, 112.96, 111.73, 102.78, 99.06, 55.86, 54.26, 49.38, 43.69, 30.50, 28.95. HRMS: calcd for $\text{C}_{28}\text{H}_{31}\text{N}_6\text{O}_3$ m/z (M+H) 499.2452, found 499.2430.

Modeling Methods. The figures of crystal structures were created using MOE version 2014.09 (Chemical Computing Group, Inc.) with the exception of Figures 1 and 9, which were created using PyMol version 1.5.0.5 (Schrodinger, LLC). The Proasis water scores were computed using Proasis version 3 (Desert Scientific Software). The model of **3** bound to CECR2 was created in MOE, starting from a crystal structure of CECR2 with ethylene glycol bound in the Kac-binding pocket (PDB: 3NXB). Chain A of this structure was superimposed to the structure of **4** in BRD9, and **3** was manually built starting from the aligned small molecule **4**. Ethylene glycol and water were removed from the CECR2 pocket, resulting in a complex of **3** and the bromodomain of CECR2. This complex was minimized using the MMFFs force field with default minimization parameters but with protein residues other than those contacting **3** fixed. Residues in the pocket were tethered with default restraints, and no restraints were used on **3** during minimization.

Molecular Modeling Coordinates

ATOM	1	N	ASP	B	438	-28.730	-13.743	-1.095	1.00	51.77	N1+
ATOM	2	CA	ASP	B	438	-28.817	-12.255	-0.923	1.00	56.42	C
ATOM	3	C	ASP	B	438	-27.465	-11.599	-1.185	1.00	62.16	C
ATOM	4	O	ASP	B	438	-26.422	-12.251	-1.121	1.00	47.27	O
ATOM	5	CB	ASP	B	438	-29.372	-11.842	0.468	1.00	57.46	C
ATOM	6	CG	ASP	B	438	-28.395	-12.094	1.643	1.00	55.41	C
ATOM	7	OD1	ASP	B	438	-28.704	-11.657	2.779	1.00	60.73	O
ATOM	8	OD2	ASP	B	438	-27.340	-12.729	1.465	1.00	61.13	O1-
ATOM	9	N	ASP	B	439	-27.504	-10.299	-1.456	1.00	57.94	N
ATOM	10	CA	ASP	B	439	-26.325	-9.571	-1.894	1.00	50.16	C
ATOM	11	C	ASP	B	439	-25.260	-9.472	-0.814	1.00	42.82	C
ATOM	12	O	ASP	B	439	-24.079	-9.517	-1.124	1.00	41.93	O
ATOM	13	CB	ASP	B	439	-26.716	-8.193	-2.421	1.00	60.81	C
ATOM	14	CG	ASP	B	439	-27.405	-8.256	-3.778	1.00	54.12	C
ATOM	15	OD1	ASP	B	439	-27.660	-9.363	-4.288	1.00	60.12	O
ATOM	16	OD2	ASP	B	439	-27.682	-7.185	-4.338	1.00	44.60	O1-
ATOM	17	N	PHE	B	440	-25.678	-9.378	0.444	1.00	36.96	N
ATOM	18	CA	PHE	B	440	-24.755	-9.413	1.586	1.00	45.25	C
ATOM	19	C	PHE	B	440	-23.862	-10.666	1.547	1.00	38.56	C
ATOM	20	O	PHE	B	440	-22.647	-10.553	1.558	1.00	37.07	O
ATOM	21	CB	PHE	B	440	-25.520	-9.373	2.931	1.00	47.85	C
ATOM	22	CG	PHE	B	440	-24.644	-9.657	4.148	1.00	46.28	C
ATOM	23	CD1	PHE	B	440	-23.923	-8.634	4.760	1.00	40.43	C
ATOM	24	CD2	PHE	B	440	-24.547	-10.948	4.673	1.00	48.58	C
ATOM	25	CE1	PHE	B	440	-23.098	-8.895	5.866	1.00	50.16	C
ATOM	26	CE2	PHE	B	440	-23.730	-11.218	5.781	1.00	58.11	C
ATOM	27	CZ	PHE	B	440	-23.003	-10.183	6.376	1.00	55.96	C
ATOM	28	N	THR	B	441	-24.480	-11.843	1.531	1.00	36.85	N
ATOM	29	CA	THR	B	441	-23.752	-13.132	1.535	1.00	36.79	C
ATOM	30	C	THR	B	441	-22.889	-13.266	0.288	1.00	31.60	C
ATOM	31	O	THR	B	441	-21.741	-13.685	0.373	1.00	35.17	O
ATOM	32	CB	THR	B	441	-24.740	-14.324	1.613	1.00	40.93	C
ATOM	33	CG2	THR	B	441	-24.028	-15.687	1.560	1.00	40.54	C
ATOM	34	OG1	THR	B	441	-25.465	-14.234	2.834	1.00	36.69	O
ATOM	35	N	ALA	B	442	-23.450	-12.876	-0.859	1.00	30.99	N
ATOM	36	CA	ALA	B	442	-22.759	-12.924	-2.117	1.00	29.01	C
ATOM	37	C	ALA	B	442	-21.507	-12.036	-2.076	1.00	32.63	C
ATOM	38	O	ALA	B	442	-20.419	-12.478	-2.432	1.00	25.61	O

ATOM	39	CB	ALA	B	442	-23.685	-12.499	-3.260	1.00	32.39	C
ATOM	40	N	MET	B	443	-21.647	-10.797	-1.615	1.00	26.92	N
ATOM	41	CA	MET	B	443	-20.515	-9.886	-1.591	1.00	25.42	C
ATOM	42	C	MET	B	443	-19.475	-10.278	-0.545	1.00	25.07	C
ATOM	43	O	MET	B	443	-18.280	-10.101	-0.747	1.00	23.13	O
ATOM	44	CB	MET	B	443	-20.981	-8.431	-1.478	1.00	27.41	C
ATOM	45	CG	MET	B	443	-21.777	-7.963	-2.725	1.00	29.20	C
ATOM	46	SD	MET	B	443	-20.895	-8.103	-4.337	1.00	37.68	S
ATOM	47	CE	MET	B	443	-21.521	-9.680	-5.010	1.00	31.72	C
ATOM	48	N	TYR	B	444	-19.927	-10.841	0.568	1.00	27.93	N
ATOM	49	CA	TYR	B	444	-18.994	-11.351	1.575	1.00	28.00	C
ATOM	50	C	TYR	B	444	-18.164	-12.503	0.969	1.00	29.90	C
ATOM	51	O	TYR	B	444	-16.964	-12.610	1.230	1.00	26.34	O
ATOM	52	CB	TYR	B	444	-19.750	-11.810	2.837	1.00	33.90	C
ATOM	53	CG	TYR	B	444	-19.017	-11.516	4.128	1.00	34.44	C
ATOM	54	CD1	TYR	B	444	-19.639	-10.830	5.149	1.00	40.07	C
ATOM	55	CD2	TYR	B	444	-17.693	-11.921	4.318	1.00	40.69	C
ATOM	56	CE1	TYR	B	444	-18.980	-10.556	6.336	1.00	45.25	C
ATOM	57	CE2	TYR	B	444	-17.020	-11.657	5.513	1.00	44.74	C
ATOM	58	CZ	TYR	B	444	-17.675	-10.970	6.519	1.00	35.53	C
ATOM	59	OH	TYR	B	444	-17.031	-10.679	7.710	1.00	40.54	O
ATOM	60	N	LYS	B	445	-18.799	-13.336	0.140	1.00	33.29	N
ATOM	61	CA	LYS	B	445	-18.078	-14.416	-0.542	1.00	35.10	C
ATOM	62	C	LYS	B	445	-16.999	-13.858	-1.443	1.00	31.32	C
ATOM	63	O	LYS	B	445	-15.872	-14.371	-1.396	1.00	30.38	O
ATOM	64	CB	LYS	B	445	-19.015	-15.343	-1.337	1.00	40.07	C
ATOM	65	CG	LYS	B	445	-19.770	-16.328	-0.442	1.00	51.11	C
ATOM	66	CD	LYS	B	445	-20.911	-17.052	-1.168	1.00	59.38	C
ATOM	67	CE	LYS	B	445	-21.646	-18.000	-0.214	1.00	57.30	C
ATOM	68	NZ	LYS	B	445	-22.890	-18.560	-0.796	1.00	63.95	N1+
ATOM	69	N	VAL	B	446	-17.351	-12.847	-2.259	1.00	27.27	N
ATOM	70	CA	VAL	B	446	-16.398	-12.121	-3.124	1.00	23.52	C
ATOM	71	C	VAL	B	446	-15.226	-11.552	-2.318	1.00	27.64	C
ATOM	72	O	VAL	B	446	-14.059	-11.675	-2.716	1.00	25.54	O
ATOM	73	CB	VAL	B	446	-17.064	-10.969	-3.929	1.00	21.35	C
ATOM	74	CG1	VAL	B	446	-15.985	-10.089	-4.677	1.00	19.09	C
ATOM	75	CG2	VAL	B	446	-18.087	-11.532	-4.933	1.00	22.24	C
ATOM	76	N	LEU	B	447	-15.537	-10.934	-1.177	1.00	23.48	N
ATOM	77	CA	LEU	B	447	-14.512	-10.332	-0.339	1.00	26.08	C
ATOM	78	C	LEU	B	447	-13.525	-11.381	0.213	1.00	22.38	C
ATOM	79	O	LEU	B	447	-12.298	-11.167	0.190	1.00	23.70	O
ATOM	80	CB	LEU	B	447	-15.152	-9.522	0.821	1.00	24.75	C
ATOM	81	CG	LEU	B	447	-14.179	-8.542	1.485	1.00	31.18	C
ATOM	82	CD1	LEU	B	447	-13.527	-7.605	0.448	1.00	40.46	C
ATOM	83	CD2	LEU	B	447	-14.860	-7.725	2.561	1.00	29.83	C
ATOM	84	N	ASP	B	448	-14.061	-12.486	0.728	1.00	26.25	N
ATOM	85	CA	ASP	B	448	-13.263	-13.610	1.221	1.00	24.99	C
ATOM	86	C	ASP	B	448	-12.359	-14.183	0.120	1.00	26.24	C
ATOM	87	O	ASP	B	448	-11.238	-14.621	0.405	1.00	25.89	O
ATOM	88	CB	ASP	B	448	-14.157	-14.751	1.748	1.00	34.85	C
ATOM	89	CG	ASP	B	448	-14.941	-14.377	3.024	1.00	42.65	C
ATOM	90	OD1	ASP	B	448	-14.456	-13.590	3.863	1.00	44.54	O
ATOM	91	OD2	ASP	B	448	-16.053	-14.896	3.181	1.00	52.11	O1-
ATOM	92	N	VAL	B	449	-12.855	-14.236	-1.122	1.00	23.89	N
ATOM	93	CA	VAL	B	449	-12.053	-14.741	-2.240	1.00	28.97	C
ATOM	94	C	VAL	B	449	-10.888	-13.792	-2.541	1.00	30.17	C
ATOM	95	O	VAL	B	449	-9.784	-14.224	-2.828	1.00	26.99	O
ATOM	96	CB	VAL	B	449	-12.933	-15.001	-3.516	1.00	27.36	C
ATOM	97	CG1	VAL	B	449	-12.065	-15.392	-4.702	1.00	30.47	C
ATOM	98	CG2	VAL	B	449	-13.948	-16.110	-3.225	1.00	31.39	C
ATOM	99	N	VAL	B	450	-11.144	-12.490	-2.468	1.00	22.14	N
ATOM	100	CA	VAL	B	450	-10.088	-11.502	-2.678	1.00	24.00	C
ATOM	101	C	VAL	B	450	-9.099	-11.557	-1.497	1.00	28.14	C

ATOM	102	O	VAL	B	450	-7.895	-11.604	-1.703	1.00	22.14	O
ATOM	103	CB	VAL	B	450	-10.671	-10.070	-2.838	1.00	24.56	C
ATOM	104	CG1	VAL	B	450	-9.546	-9.048	-2.919	1.00	23.93	C
ATOM	105	CG2	VAL	B	450	-11.550	-9.983	-4.086	1.00	23.61	C
ATOM	106	N	LYS	B	451	-9.624	-11.611	-0.274	1.00	24.17	N
ATOM	107	CA	LYS	B	451	-8.794	-11.700	0.912	1.00	26.44	C
ATOM	108	C	LYS	B	451	-7.901	-12.950	0.827	1.00	29.24	C
ATOM	109	O	LYS	B	451	-6.718	-12.894	1.169	1.00	29.81	O
ATOM	110	CB	LYS	B	451	-9.659	-11.756	2.189	1.00	29.31	C
ATOM	111	CG	LYS	B	451	-8.919	-11.350	3.458	1.00	33.98	C
ATOM	112	CD	LYS	B	451	-9.524	-11.913	4.774	1.00	44.17	C
ATOM	113	CE	LYS	B	451	-10.959	-11.524	5.032	1.00	43.86	C
ATOM	114	NZ	LYS	B	451	-11.335	-11.767	6.484	1.00	35.88	N1+
ATOM	115	N	ALA	B	452	-8.467	-14.076	0.375	1.00	26.61	N
ATOM	116	CA	ALA	B	452	-7.711	-15.334	0.264	1.00	29.35	C
ATOM	117	C	ALA	B	452	-6.569	-15.318	-0.765	1.00	33.20	C
ATOM	118	O	ALA	B	452	-5.687	-16.161	-0.720	1.00	29.44	O
ATOM	119	CB	ALA	B	452	-8.657	-16.473	-0.065	1.00	32.51	C
ATOM	120	N	HIS	B	453	-6.582	-14.392	-1.706	1.00	27.83	N
ATOM	121	CA	HIS	B	453	-5.543	-14.328	-2.725	1.00	28.12	C
ATOM	122	C	HIS	B	453	-4.156	-14.018	-2.152	1.00	24.98	C
ATOM	123	O	HIS	B	453	-4.007	-13.188	-1.261	1.00	27.78	O
ATOM	124	CB	HIS	B	453	-5.924	-13.269	-3.768	1.00	28.02	C
ATOM	125	CG	HIS	B	453	-5.148	-13.360	-5.046	1.00	25.43	C
ATOM	126	CD2	HIS	B	453	-5.466	-13.899	-6.250	1.00	26.05	C
ATOM	127	ND1	HIS	B	453	-3.885	-12.821	-5.188	1.00	25.33	N
ATOM	128	CE1	HIS	B	453	-3.455	-13.039	-6.423	1.00	31.25	C
ATOM	129	NE2	HIS	B	453	-4.403	-13.675	-7.092	1.00	27.35	N
ATOM	130	N	LYS	B	454	-3.141	-14.706	-2.653	1.00	24.73	N
ATOM	131	CA	LYS	B	454	-1.757	-14.532	-2.186	1.00	26.62	C
ATOM	132	C	LYS	B	454	-1.259	-13.069	-2.258	1.00	25.84	C
ATOM	133	O	LYS	B	454	-0.428	-12.665	-1.465	1.00	26.19	O
ATOM	134	CB	LYS	B	454	-0.834	-15.478	-2.996	1.00	27.73	C
ATOM	135	CG	LYS	B	454	-0.645	-15.068	-4.467	1.00	30.83	C
ATOM	136	CD	LYS	B	454	0.282	-16.059	-5.190	1.00	38.87	C
ATOM	137	CE	LYS	B	454	0.565	-15.644	-6.640	1.00	0.00	C
ATOM	138	NZ	LYS	B	454	1.406	-14.422	-6.722	1.00	0.00	N1+
ATOM	139	N	ASP	B	455	-1.757	-12.289	-3.206	1.00	24.11	N
ATOM	140	CA	ASP	B	455	-1.348	-10.883	-3.303	1.00	25.33	C
ATOM	141	C	ASP	B	455	-2.209	-9.913	-2.475	1.00	28.22	C
ATOM	142	O	ASP	B	455	-2.082	-8.697	-2.643	1.00	25.03	O
ATOM	143	CB	ASP	B	455	-1.327	-10.441	-4.770	1.00	21.53	C
ATOM	144	CG	ASP	B	455	-0.188	-11.068	-5.556	1.00	23.58	C
ATOM	145	OD1	ASP	B	455	0.824	-11.453	-4.949	1.00	25.27	O
ATOM	146	OD2	ASP	B	455	-0.318	-11.175	-6.776	1.00	30.81	O1-
ATOM	147	N	SER	B	456	-3.048	-10.416	-1.559	1.00	25.40	N
ATOM	148	CA	SER	B	456	-3.936	-9.506	-0.808	1.00	22.65	C
ATOM	149	C	SER	B	456	-3.212	-8.769	0.324	1.00	27.48	C
ATOM	150	O	SER	B	456	-3.691	-7.743	0.780	1.00	23.32	O
ATOM	151	CB	SER	B	456	-5.109	-10.247	-0.185	1.00	22.19	C
ATOM	152	OG	SER	B	456	-4.637	-11.108	0.837	1.00	21.75	O
ATOM	153	N	TRP	B	457	-2.072	-9.297	0.777	1.00	23.74	N
ATOM	154	CA	TRP	B	457	-1.470	-8.860	2.045	1.00	23.09	C
ATOM	155	C	TRP	B	457	-1.229	-7.333	2.181	1.00	19.92	C
ATOM	156	O	TRP	B	457	-1.456	-6.817	3.242	1.00	23.66	O
ATOM	157	CB	TRP	B	457	-0.218	-9.703	2.446	1.00	25.44	C
ATOM	158	CG	TRP	B	457	0.955	-9.543	1.536	1.00	29.22	C
ATOM	159	CD1	TRP	B	457	1.303	-10.363	0.499	1.00	30.22	C
ATOM	160	CD2	TRP	B	457	1.960	-8.520	1.594	1.00	27.45	C
ATOM	161	CE2	TRP	B	457	2.875	-8.775	0.552	1.00	33.88	C
ATOM	162	CE3	TRP	B	457	2.173	-7.409	2.425	1.00	30.50	C
ATOM	163	NE1	TRP	B	457	2.448	-9.897	-0.107	1.00	31.95	N
ATOM	164	CZ2	TRP	B	457	3.972	-7.942	0.292	1.00	35.92	C

ATOM	165	CZ3	TRP	B	457	3.273	-6.588	2.171	1.00	32.28	C
ATOM	166	CH2	TRP	B	457	4.155	-6.863	1.105	1.00	33.49	C
ATOM	167	N	PRO	B	458	-0.844	-6.602	1.091	1.00	21.46	N
ATOM	168	CA	PRO	B	458	-0.670	-5.155	1.273	1.00	22.29	C
ATOM	169	C	PRO	B	458	-1.964	-4.364	1.469	1.00	22.13	C
ATOM	170	O	PRO	B	458	-1.908	-3.181	1.806	1.00	22.00	O
ATOM	171	CB	PRO	B	458	-0.001	-4.703	-0.039	1.00	24.12	C
ATOM	172	CG	PRO	B	458	0.544	-6.009	-0.696	1.00	23.57	C
ATOM	173	CD	PRO	B	458	-0.483	-7.019	-0.287	1.00	21.95	C
ATOM	174	N	PHE	B	459	-3.101	-5.006	1.246	1.00	25.61	N
ATOM	175	CA	PHE	B	459	-4.397	-4.345	1.094	1.00	23.65	C
ATOM	176	C	PHE	B	459	-5.325	-4.769	2.226	1.00	23.44	C
ATOM	177	O	PHE	B	459	-6.482	-4.393	2.245	1.00	20.65	O
ATOM	178	CB	PHE	B	459	-5.026	-4.783	-0.241	1.00	24.70	C
ATOM	179	CG	PHE	B	459	-4.149	-4.522	-1.417	1.00	23.89	C
ATOM	180	CD1	PHE	B	459	-4.028	-3.240	-1.922	1.00	23.33	C
ATOM	181	CD2	PHE	B	459	-3.360	-5.536	-1.973	1.00	21.83	C
ATOM	182	CE1	PHE	B	459	-3.148	-2.952	-2.948	1.00	27.96	C
ATOM	183	CE2	PHE	B	459	-2.492	-5.261	-3.038	1.00	23.60	C
ATOM	184	CZ	PHE	B	459	-2.376	-3.983	-3.519	1.00	26.07	C
ATOM	185	N	LEU	B	460	-4.819	-5.566	3.168	1.00	23.72	N
ATOM	186	CA	LEU	B	460	-5.660	-6.150	4.225	1.00	23.50	C
ATOM	187	C	LEU	B	460	-6.102	-5.135	5.260	1.00	26.89	C
ATOM	188	O	LEU	B	460	-7.165	-5.283	5.866	1.00	25.98	O
ATOM	189	CB	LEU	B	460	-4.937	-7.295	4.937	1.00	24.37	C
ATOM	190	CG	LEU	B	460	-4.725	-8.561	4.102	1.00	23.37	C
ATOM	191	CD1	LEU	B	460	-3.966	-9.682	4.838	1.00	25.91	C
ATOM	192	CD2	LEU	B	460	-6.051	-9.083	3.570	1.00	27.11	C
ATOM	193	N	GLU	B	461	-5.282	-4.115	5.471	1.00	25.18	N
ATOM	194	CA	GLU	B	461	-5.551	-3.139	6.514	1.00	24.92	C
ATOM	195	C	GLU	B	461	-5.360	-1.744	5.956	1.00	22.12	C
ATOM	196	O	GLU	B	461	-4.668	-1.588	4.969	1.00	23.83	O
ATOM	197	CB	GLU	B	461	-4.570	-3.351	7.657	1.00	26.18	C
ATOM	198	CG	GLU	B	461	-4.934	-4.501	8.555	1.00	31.06	C
ATOM	199	CD	GLU	B	461	-3.946	-4.684	9.704	1.00	30.23	C
ATOM	200	OE1	GLU	B	461	-2.767	-4.986	9.442	1.00	34.71	O
ATOM	201	OE2	GLU	B	461	-4.371	-4.543	10.850	1.00	36.32	O1-
ATOM	202	N	PRO	B	462	-5.923	-0.724	6.629	1.00	21.01	N
ATOM	203	CA	PRO	B	462	-5.637	0.640	6.242	1.00	22.25	C
ATOM	204	C	PRO	B	462	-4.129	0.903	6.149	1.00	24.43	C
ATOM	205	O	PRO	B	462	-3.329	0.399	6.985	1.00	23.97	O
ATOM	206	CB	PRO	B	462	-6.259	1.472	7.364	1.00	26.14	C
ATOM	207	CG	PRO	B	462	-7.270	0.584	8.001	1.00	28.29	C
ATOM	208	CD	PRO	B	462	-6.800	-0.805	7.819	1.00	26.93	C
ATOM	209	N	VAL	B	463	-3.747	1.695	5.155	1.00	24.51	N
ATOM	210	CA	VAL	B	463	-2.354	1.977	4.905	1.00	26.26	C
ATOM	211	C	VAL	B	463	-1.773	2.756	6.096	1.00	31.49	C
ATOM	212	O	VAL	B	463	-2.372	3.727	6.573	1.00	28.31	O
ATOM	213	CB	VAL	B	463	-2.169	2.771	3.604	1.00	31.84	C
ATOM	214	CG1	VAL	B	463	-0.724	3.230	3.454	1.00	25.77	C
ATOM	215	CG2	VAL	B	463	-2.646	1.936	2.406	1.00	24.00	C
ATOM	216	N	ASP	B	464	-0.609	2.315	6.568	1.00	29.88	N
ATOM	217	CA	ASP	B	464	0.123	2.970	7.665	1.00	32.13	C
ATOM	218	C	ASP	B	464	1.087	3.944	7.008	1.00	33.38	C
ATOM	219	O	ASP	B	464	1.979	3.512	6.255	1.00	31.14	O
ATOM	220	CB	ASP	B	464	0.892	1.915	8.453	1.00	38.09	C
ATOM	221	CG	ASP	B	464	1.616	2.476	9.676	1.00	36.64	C
ATOM	222	OD1	ASP	B	464	1.928	3.689	9.767	1.00	34.96	O
ATOM	223	OD2	ASP	B	464	1.889	1.662	10.564	1.00	40.48	O1-
ATOM	224	N	GLU	B	465	0.897	5.240	7.270	1.00	30.58	N
ATOM	225	CA	GLU	B	465	1.741	6.281	6.673	1.00	33.61	C
ATOM	226	C	GLU	B	465	3.246	6.164	6.963	1.00	41.41	C
ATOM	227	O	GLU	B	465	4.048	6.751	6.234	1.00	38.37	O

ATOM	228	CB	GLU	B	465	1.273	7.704	7.055	1.00	34.67	C
ATOM	229	CG	GLU	B	465	0.675	8.448	5.894	1.00	42.56	C
ATOM	230	CD	GLU	B	465	0.360	9.921	6.162	1.00	50.81	C
ATOM	231	OE1	GLU	B	465	-0.389	10.519	5.348	1.00	44.26	O
ATOM	232	OE2	GLU	B	465	0.847	10.483	7.163	1.00	46.54	O1-
ATOM	233	N	SER	B	466	3.656	5.428	7.995	1.00	41.90	N
ATOM	234	CA	SER	B	466	5.104	5.288	8.227	1.00	48.42	C
ATOM	235	C	SER	B	466	5.771	4.261	7.286	1.00	55.44	C
ATOM	236	O	SER	B	466	6.986	4.162	7.256	1.00	53.98	O
ATOM	237	CB	SER	B	466	5.443	5.039	9.716	1.00	54.15	C
ATOM	238	OG	SER	B	466	4.534	4.176	10.355	1.00	56.88	O
ATOM	239	N	TYR	B	467	4.980	3.517	6.512	1.00	38.08	N
ATOM	240	CA	TYR	B	467	5.490	2.631	5.463	1.00	41.92	C
ATOM	241	C	TYR	B	467	4.958	3.083	4.080	1.00	36.62	C
ATOM	242	O	TYR	B	467	5.078	2.353	3.094	1.00	37.70	O
ATOM	243	CB	TYR	B	467	5.094	1.168	5.747	1.00	38.23	C
ATOM	244	CG	TYR	B	467	5.503	0.631	7.110	1.00	56.36	C
ATOM	245	CD1	TYR	B	467	6.714	-0.046	7.294	1.00	53.94	C
ATOM	246	CD2	TYR	B	467	4.671	0.786	8.214	1.00	52.35	C
ATOM	247	CE1	TYR	B	467	7.078	-0.535	8.544	1.00	53.63	C
ATOM	248	CE2	TYR	B	467	5.026	0.312	9.452	1.00	52.82	C
ATOM	249	CZ	TYR	B	467	6.226	-0.351	9.621	1.00	53.64	C
ATOM	250	OH	TYR	B	467	6.557	-0.830	10.875	1.00	60.65	O
ATOM	251	N	ALA	B	468	4.374	4.287	4.046	1.00	37.90	N
ATOM	252	CA	ALA	B	468	3.681	4.856	2.876	1.00	39.01	C
ATOM	253	C	ALA	B	468	3.644	6.364	3.039	1.00	35.48	C
ATOM	254	O	ALA	B	468	2.570	6.970	3.252	1.00	32.78	O
ATOM	255	CB	ALA	B	468	2.277	4.287	2.742	1.00	31.10	C
ATOM	256	N	PRO	B	469	4.825	7.004	2.973	1.00	44.04	N
ATOM	257	CA	PRO	B	469	4.935	8.439	3.212	1.00	37.48	C
ATOM	258	C	PRO	B	469	3.933	9.278	2.453	1.00	36.24	C
ATOM	259	O	PRO	B	469	3.710	9.054	1.254	1.00	35.42	O
ATOM	260	CB	PRO	B	469	6.355	8.768	2.733	1.00	36.88	C
ATOM	261	CG	PRO	B	469	7.115	7.533	2.943	1.00	40.54	C
ATOM	262	CD	PRO	B	469	6.157	6.378	2.829	1.00	54.65	C
ATOM	263	N	ASN	B	470	3.346	10.247	3.150	1.00	30.54	N
ATOM	264	CA	ASN	B	470	2.379	11.173	2.554	1.00	33.10	C
ATOM	265	C	ASN	B	470	1.047	10.571	2.024	1.00	27.75	C
ATOM	266	O	ASN	B	470	0.299	11.249	1.308	1.00	24.89	O
ATOM	267	CB	ASN	B	470	3.061	11.895	1.405	1.00	43.37	C
ATOM	268	CG	ASN	B	470	2.590	13.296	1.250	1.00	47.35	C
ATOM	269	ND2	ASN	B	470	2.293	13.688	0.013	1.00	46.84	N
ATOM	270	OD1	ASN	B	470	2.522	14.041	2.221	1.00	54.68	O
ATOM	271	N	TYR	B	471	0.777	9.314	2.335	1.00	29.04	N
ATOM	272	CA	TYR	B	471	-0.362	8.598	1.741	1.00	30.02	C
ATOM	273	C	TYR	B	471	-1.708	9.352	1.843	1.00	28.03	C
ATOM	274	O	TYR	B	471	-2.441	9.473	0.854	1.00	24.97	O
ATOM	275	CB	TYR	B	471	-0.522	7.203	2.381	1.00	28.12	C
ATOM	276	CG	TYR	B	471	-1.505	6.344	1.627	1.00	23.91	C
ATOM	277	CD1	TYR	B	471	-2.831	6.244	2.048	1.00	21.57	C
ATOM	278	CD2	TYR	B	471	-1.109	5.649	0.449	1.00	24.47	C
ATOM	279	CE1	TYR	B	471	-3.756	5.459	1.330	1.00	22.49	C
ATOM	280	CE2	TYR	B	471	-1.998	4.865	-0.264	1.00	22.57	C
ATOM	281	CZ	TYR	B	471	-3.337	4.781	0.178	1.00	23.59	C
ATOM	282	OH	TYR	B	471	-4.234	4.037	-0.495	1.00	20.61	O
ATOM	283	N	TYR	B	472	-2.031	9.859	3.019	1.00	25.92	N
ATOM	284	CA	TYR	B	472	-3.366	10.444	3.237	1.00	26.03	C
ATOM	285	C	TYR	B	472	-3.501	11.859	2.672	1.00	33.30	C
ATOM	286	O	TYR	B	472	-4.608	12.375	2.516	1.00	30.84	O
ATOM	287	CB	TYR	B	472	-3.782	10.342	4.691	1.00	27.48	C
ATOM	288	CG	TYR	B	472	-4.002	8.915	5.081	1.00	22.28	C
ATOM	289	CD1	TYR	B	472	-3.043	8.221	5.826	1.00	27.47	C
ATOM	290	CD2	TYR	B	472	-5.131	8.228	4.666	1.00	23.18	C

ATOM	291	CE1	TYR	B	472	-3.206	6.884	6.150	1.00	25.14	C
ATOM	292	CE2	TYR	B	472	-5.308	6.881	4.997	1.00	24.81	C
ATOM	293	CZ	TYR	B	472	-4.340	6.225	5.745	1.00	24.30	C
ATOM	294	OH	TYR	B	472	-4.514	4.928	6.062	1.00	24.43	O
ATOM	295	N	GLN	B	473	-2.376	12.455	2.295	1.00	34.76	N
ATOM	296	CA	GLN	B	473	-2.409	13.695	1.521	1.00	41.34	C
ATOM	297	C	GLN	B	473	-2.694	13.430	0.050	1.00	28.18	C
ATOM	298	O	GLN	B	473	-3.343	14.236	-0.607	1.00	37.77	O
ATOM	299	CB	GLN	B	473	-1.100	14.470	1.677	1.00	57.10	C
ATOM	300	CG	GLN	B	473	-1.113	15.852	1.028	1.00	71.05	C
ATOM	301	CD	GLN	B	473	0.145	16.633	1.336	1.00	82.32	C
ATOM	302	NE2	GLN	B	473	0.231	17.165	2.553	1.00	78.55	N
ATOM	303	OE1	GLN	B	473	1.045	16.739	0.499	1.00	76.25	O
ATOM	304	N	ILE	B	474	-2.225	12.307	-0.471	1.00	29.39	N
ATOM	305	CA	ILE	B	474	-2.434	11.975	-1.879	1.00	28.05	C
ATOM	306	C	ILE	B	474	-3.795	11.281	-2.121	1.00	31.31	C
ATOM	307	O	ILE	B	474	-4.500	11.596	-3.090	1.00	24.16	O
ATOM	308	CB	ILE	B	474	-1.294	11.073	-2.391	1.00	34.50	C
ATOM	309	CG1	ILE	B	474	0.022	11.875	-2.418	1.00	35.49	C
ATOM	310	CG2	ILE	B	474	-1.609	10.556	-3.801	1.00	26.94	C
ATOM	311	CD1	ILE	B	474	1.264	11.041	-2.349	1.00	39.01	C
ATOM	312	N	ILE	B	475	-4.155	10.361	-1.224	1.00	23.21	N
ATOM	313	CA	ILE	B	475	-5.324	9.491	-1.401	1.00	22.39	C
ATOM	314	C	ILE	B	475	-6.469	9.946	-0.468	1.00	20.46	C
ATOM	315	O	ILE	B	475	-6.387	9.786	0.754	1.00	23.58	O
ATOM	316	CB	ILE	B	475	-4.924	8.004	-1.160	1.00	18.95	C
ATOM	317	CG1	ILE	B	475	-3.905	7.541	-2.204	1.00	22.04	C
ATOM	318	CG2	ILE	B	475	-6.185	7.077	-1.144	1.00	22.10	C
ATOM	319	CD1	ILE	B	475	-4.411	7.549	-3.684	1.00	20.47	C
ATOM	320	N	LYS	B	476	-7.528	10.508	-1.073	1.00	23.75	N
ATOM	321	CA	LYS	B	476	-8.622	11.150	-0.331	1.00	24.88	C
ATOM	322	C	LYS	B	476	-9.750	10.205	0.083	1.00	22.05	C
ATOM	323	O	LYS	B	476	-10.538	10.526	0.986	1.00	24.95	O
ATOM	324	CB	LYS	B	476	-9.187	12.318	-1.153	1.00	30.48	C
ATOM	325	CG	LYS	B	476	-8.147	13.430	-1.468	1.00	40.76	C
ATOM	326	CD	LYS	B	476	-7.411	13.800	-0.196	1.00	43.90	C
ATOM	327	CE	LYS	B	476	-6.555	15.023	-0.336	1.00	49.25	C
ATOM	328	NZ	LYS	B	476	-5.944	15.242	0.997	1.00	49.82	N1+
ATOM	329	N	ALA	B	477	-9.834	9.051	-0.577	1.00	21.77	N
ATOM	330	CA	ALA	B	477	-10.811	8.007	-0.255	1.00	20.17	C
ATOM	331	C	ALA	B	477	-10.070	6.665	-0.032	1.00	18.44	C
ATOM	332	O	ALA	B	477	-10.135	5.752	-0.842	1.00	21.52	O
ATOM	333	CB	ALA	B	477	-11.908	7.886	-1.350	1.00	20.70	C
ATOM	334	N	PRO	B	478	-9.372	6.547	1.098	1.00	20.97	N
ATOM	335	CA	PRO	B	478	-8.646	5.320	1.334	1.00	21.94	C
ATOM	336	C	PRO	B	478	-9.621	4.165	1.496	1.00	23.13	C
ATOM	337	O	PRO	B	478	-10.754	4.358	1.979	1.00	20.34	O
ATOM	338	CB	PRO	B	478	-7.866	5.584	2.632	1.00	22.44	C
ATOM	339	CG	PRO	B	478	-8.481	6.854	3.213	1.00	23.79	C
ATOM	340	CD	PRO	B	478	-9.083	7.591	2.092	1.00	17.91	C
ATOM	341	N	MET	B	479	-9.163	2.976	1.100	1.00	19.63	N
ATOM	342	CA	MET	B	479	-9.950	1.781	1.232	1.00	20.08	C
ATOM	343	C	MET	B	479	-9.054	0.565	1.377	1.00	19.31	C
ATOM	344	O	MET	B	479	-7.956	0.537	0.847	1.00	20.71	O
ATOM	345	CB	MET	B	479	-10.882	1.616	0.001	1.00	20.18	C
ATOM	346	CG	MET	B	479	-12.011	0.557	0.171	1.00	21.13	C
ATOM	347	SD	MET	B	479	-12.941	0.620	1.722	1.00	24.16	S
ATOM	348	CE	MET	B	479	-13.633	2.334	1.634	1.00	21.03	C
ATOM	349	N	ASP	B	480	-9.533	-0.433	2.108	1.00	18.97	N
ATOM	350	CA	ASP	B	480	-8.784	-1.652	2.255	1.00	18.26	C
ATOM	351	C	ASP	B	480	-9.775	-2.739	2.595	1.00	17.65	C
ATOM	352	O	ASP	B	480	-10.966	-2.467	2.870	1.00	16.93	O
ATOM	353	CB	ASP	B	480	-7.773	-1.503	3.384	1.00	20.69	C

ATOM	354	CG	ASP	B	480	-8.459	-1.240	4.690	1.00	23.79	C
ATOM	355	OD1	ASP	B	480	-8.865	-0.068	4.986	1.00	21.90	O
ATOM	356	OD2	ASP	B	480	-8.682	-2.255	5.362	1.00	21.59	O1-
ATOM	357	N	ILE	B	481	-9.276	-3.975	2.594	1.00	14.92	N
ATOM	358	CA	ILE	B	481	-10.172	-5.146	2.821	1.00	17.12	C
ATOM	359	C	ILE	B	481	-10.837	-5.184	4.182	1.00	19.83	C
ATOM	360	O	ILE	B	481	-12.035	-5.524	4.288	1.00	19.23	O
ATOM	361	CB	ILE	B	481	-9.469	-6.486	2.466	1.00	18.17	C
ATOM	362	CG1	ILE	B	481	-9.100	-6.513	0.991	1.00	20.23	C
ATOM	363	CG2	ILE	B	481	-10.359	-7.692	2.879	1.00	21.75	C
ATOM	364	CD1	ILE	B	481	-7.933	-7.474	0.617	1.00	18.14	C
ATOM	365	N	SER	B	482	-10.083	-4.808	5.222	1.00	19.18	N
ATOM	366	CA	SER	B	482	-10.594	-4.782	6.591	1.00	23.68	C
ATOM	367	C	SER	B	482	-11.784	-3.803	6.702	1.00	20.70	C
ATOM	368	O	SER	B	482	-12.850	-4.130	7.263	1.00	21.26	O
ATOM	369	CB	SER	B	482	-9.475	-4.395	7.558	1.00	22.67	C
ATOM	370	OG	SER	B	482	-10.013	-4.095	8.831	1.00	40.64	O
ATOM	371	N	SER	B	483	-11.606	-2.622	6.118	1.00	19.36	N
ATOM	372	CA	SER	B	483	-12.652	-1.613	6.093	1.00	20.52	C
ATOM	373	C	SER	B	483	-13.894	-2.117	5.341	1.00	19.87	C
ATOM	374	O	SER	B	483	-15.021	-1.903	5.794	1.00	19.75	O
ATOM	375	CB	SER	B	483	-12.106	-0.275	5.554	1.00	21.70	C
ATOM	376	OG	SER	B	483	-11.080	0.239	6.444	1.00	20.80	O
ATOM	377	N	MET	B	484	-13.712	-2.828	4.223	1.00	20.61	N
ATOM	378	CA	MET	B	484	-14.857	-3.303	3.451	1.00	22.20	C
ATOM	379	C	MET	B	484	-15.603	-4.355	4.277	1.00	23.88	C
ATOM	380	O	MET	B	484	-16.854	-4.382	4.323	1.00	22.73	O
ATOM	381	CB	MET	B	484	-14.437	-3.824	2.066	1.00	21.70	C
ATOM	382	CG	MET	B	484	-14.056	-2.707	1.092	1.00	22.95	C
ATOM	383	SD	MET	B	484	-13.666	-3.284	-0.583	1.00	22.83	S
ATOM	384	CE	MET	B	484	-12.020	-3.909	-0.305	1.00	17.77	C
ATOM	385	N	GLU	B	485	-14.849	-5.153	5.015	1.00	21.56	N
ATOM	386	CA	GLU	B	485	-15.453	-6.187	5.842	1.00	25.03	C
ATOM	387	C	GLU	B	485	-16.289	-5.604	6.999	1.00	24.05	C
ATOM	388	O	GLU	B	485	-17.411	-6.056	7.264	1.00	24.00	O
ATOM	389	CB	GLU	B	485	-14.364	-7.145	6.347	1.00	25.77	C
ATOM	390	CG	GLU	B	485	-14.955	-8.365	6.968	1.00	30.57	C
ATOM	391	CD	GLU	B	485	-13.994	-9.553	7.033	1.00	34.77	C
ATOM	392	OE1	GLU	B	485	-12.797	-9.445	6.650	1.00	32.37	O
ATOM	393	OE2	GLU	B	485	-14.482	-10.607	7.506	1.00	34.48	O1-
ATOM	394	N	LYS	B	486	-15.745	-4.587	7.659	1.00	26.00	N
ATOM	395	CA	LYS	B	486	-16.457	-3.854	8.683	1.00	25.29	C
ATOM	396	C	LYS	B	486	-17.704	-3.160	8.129	1.00	23.02	C
ATOM	397	O	LYS	B	486	-18.694	-3.051	8.821	1.00	22.58	O
ATOM	398	CB	LYS	B	486	-15.575	-2.798	9.374	1.00	29.32	C
ATOM	399	CG	LYS	B	486	-14.437	-3.284	10.309	1.00	33.42	C
ATOM	400	CD	LYS	B	486	-13.454	-2.128	10.406	1.00	39.36	C
ATOM	401	CE	LYS	B	486	-12.578	-2.083	11.627	1.00	54.51	C
ATOM	402	NZ	LYS	B	486	-12.024	-0.676	11.698	1.00	38.28	N1+
ATOM	403	N	LYS	B	487	-17.663	-2.679	6.900	1.00	21.60	N
ATOM	404	CA	LYS	B	487	-18.807	-1.966	6.328	1.00	24.00	C
ATOM	405	C	LYS	B	487	-19.883	-2.986	5.970	1.00	24.31	C
ATOM	406	O	LYS	B	487	-21.070	-2.785	6.256	1.00	25.41	O
ATOM	407	CB	LYS	B	487	-18.391	-1.141	5.112	1.00	22.98	C
ATOM	408	CG	LYS	B	487	-17.581	0.080	5.458	1.00	21.34	C
ATOM	409	CD	LYS	B	487	-17.112	0.886	4.233	1.00	20.12	C
ATOM	410	CE	LYS	B	487	-18.252	1.607	3.497	1.00	20.30	C
ATOM	411	NZ	LYS	B	487	-17.670	2.492	2.430	1.00	17.88	N1+
ATOM	412	N	LEU	B	488	-19.459	-4.120	5.416	1.00	23.08	N
ATOM	413	CA	LEU	B	488	-20.391	-5.233	5.248	1.00	29.13	C
ATOM	414	C	LEU	B	488	-21.084	-5.644	6.535	1.00	28.20	C
ATOM	415	O	LEU	B	488	-22.300	-5.714	6.562	1.00	26.47	O
ATOM	416	CB	LEU	B	488	-19.699	-6.468	4.665	1.00	28.78	C

ATOM	417	CG	LEU	B	488	-19.580	-6.482	3.159	1.00	34.58	C
ATOM	418	CD1	LEU	B	488	-18.656	-7.636	2.841	1.00	28.49	C
ATOM	419	CD2	LEU	B	488	-20.956	-6.582	2.448	1.00	33.37	C
ATOM	420	N	ASN	B	489	-20.298	-5.932	7.582	1.00	27.32	N
ATOM	421	CA	ASN	B	489	-20.846	-6.361	8.857	1.00	28.16	C
ATOM	422	C	ASN	B	489	-21.684	-5.255	9.511	1.00	34.39	C
ATOM	423	O	ASN	B	489	-22.641	-5.549	10.203	1.00	33.26	O
ATOM	424	CB	ASN	B	489	-19.740	-6.795	9.818	1.00	30.48	C
ATOM	425	CG	ASN	B	489	-19.133	-8.105	9.424	1.00	35.08	C
ATOM	426	ND2	ASN	B	489	-17.817	-8.162	9.353	1.00	36.51	N
ATOM	427	OD1	ASN	B	489	-19.853	-9.066	9.196	1.00	41.25	O
ATOM	428	N	GLY	B	490	-21.319	-3.992	9.280	1.00	31.29	N
ATOM	429	CA	GLY	B	490	-21.987	-2.867	9.896	1.00	29.24	C
ATOM	430	C	GLY	B	490	-23.219	-2.398	9.145	1.00	30.69	C
ATOM	431	O	GLY	B	490	-23.841	-1.420	9.555	1.00	27.42	O
ATOM	432	N	GLY	B	491	-23.596	-3.085	8.065	1.00	27.00	N
ATOM	433	CA	GLY	B	491	-24.725	-2.655	7.239	1.00	29.29	C
ATOM	434	C	GLY	B	491	-24.559	-1.262	6.616	1.00	28.06	C
ATOM	435	O	GLY	B	491	-25.531	-0.528	6.420	1.00	25.41	O
ATOM	436	N	LEU	B	492	-23.332	-0.914	6.269	1.00	25.58	N
ATOM	437	CA	LEU	B	492	-22.994	0.404	5.717	1.00	25.03	C
ATOM	438	C	LEU	B	492	-22.956	0.454	4.194	1.00	21.88	C
ATOM	439	O	LEU	B	492	-22.556	1.468	3.616	1.00	26.89	O
ATOM	440	CB	LEU	B	492	-21.655	0.865	6.276	1.00	24.97	C
ATOM	441	CG	LEU	B	492	-21.699	1.362	7.720	1.00	25.84	C
ATOM	442	CD1	LEU	B	492	-20.322	1.344	8.297	1.00	22.29	C
ATOM	443	CD2	LEU	B	492	-22.336	2.787	7.849	1.00	22.74	C
ATOM	444	N	TYR	B	493	-23.335	-0.632	3.545	1.00	21.54	N
ATOM	445	CA	TYR	B	493	-23.645	-0.609	2.107	1.00	24.54	C
ATOM	446	C	TYR	B	493	-25.145	-0.663	1.872	1.00	23.91	C
ATOM	447	O	TYR	B	493	-25.827	-1.563	2.380	1.00	27.16	O
ATOM	448	CB	TYR	B	493	-22.994	-1.783	1.363	1.00	21.73	C
ATOM	449	CG	TYR	B	493	-21.498	-1.726	1.374	1.00	21.91	C
ATOM	450	CD1	TYR	B	493	-20.809	-0.688	0.730	1.00	19.48	C
ATOM	451	CD2	TYR	B	493	-20.754	-2.674	2.044	1.00	21.29	C
ATOM	452	CE1	TYR	B	493	-19.429	-0.614	0.752	1.00	22.39	C
ATOM	453	CE2	TYR	B	493	-19.325	-2.631	2.048	1.00	22.22	C
ATOM	454	CZ	TYR	B	493	-18.673	-1.599	1.401	1.00	21.69	C
ATOM	455	OH	TYR	B	493	-17.294	-1.494	1.418	1.00	22.06	O
ATOM	456	N	CYS	B	494	-25.656	0.284	1.088	1.00	24.27	N
ATOM	457	CA	CYS	B	494	-27.059	0.305	0.698	1.00	28.60	C
ATOM	458	C	CYS	B	494	-27.310	-0.595	-0.496	1.00	28.51	C
ATOM	459	O	CYS	B	494	-28.401	-1.118	-0.627	1.00	30.87	O
ATOM	460	CB	CYS	B	494	-27.535	1.738	0.374	1.00	26.96	C
ATOM	461	SG	CYS	B	494	-27.343	2.853	1.789	1.00	28.24	S
ATOM	462	N	THR	B	495	-26.320	-0.769	-1.364	1.00	24.42	N
ATOM	463	CA	THR	B	495	-26.469	-1.628	-2.524	1.00	23.73	C
ATOM	464	C	THR	B	495	-25.142	-2.319	-2.851	1.00	25.27	C
ATOM	465	O	THR	B	495	-24.065	-1.913	-2.380	1.00	23.62	O
ATOM	466	CB	THR	B	495	-26.870	-0.850	-3.810	1.00	25.65	C
ATOM	467	CG2	THR	B	495	-28.275	-0.146	-3.666	1.00	26.96	C
ATOM	468	OG1	THR	B	495	-25.820	0.072	-4.149	1.00	24.23	O
ATOM	469	N	LYS	B	496	-25.259	-3.327	-3.709	1.00	26.91	N
ATOM	470	CA	LYS	B	496	-24.108	-4.103	-4.226	1.00	31.14	C
ATOM	471	C	LYS	B	496	-23.090	-3.189	-4.886	1.00	23.38	C
ATOM	472	O	LYS	B	496	-21.912	-3.280	-4.634	1.00	25.71	O
ATOM	473	CB	LYS	B	496	-24.625	-5.112	-5.258	1.00	34.39	C
ATOM	474	CG	LYS	B	496	-23.703	-6.222	-5.655	1.00	52.19	C
ATOM	475	CD	LYS	B	496	-24.473	-7.277	-6.507	1.00	54.10	C
ATOM	476	CE	LYS	B	496	-23.589	-7.900	-7.598	1.00	65.42	C
ATOM	477	NZ	LYS	B	496	-24.015	-9.274	-8.031	1.00	53.52	N1+
ATOM	478	N	GLU	B	497	-23.554	-2.306	-5.749	1.00	24.21	N
ATOM	479	CA	GLU	B	497	-22.684	-1.399	-6.500	1.00	26.92	C

ATOM	480	C	GLU	B	497	-21.782	-0.532	-5.594	1.00	20.91	C
ATOM	481	O	GLU	B	497	-20.667	-0.187	-5.967	1.00	21.60	O
ATOM	482	CB	GLU	B	497	-23.598	-0.521	-7.397	1.00	29.67	C
ATOM	483	CG	GLU	B	497	-22.917	0.456	-8.339	1.00	36.55	C
ATOM	484	CD	GLU	B	497	-23.914	1.464	-8.971	1.00	52.45	C
ATOM	485	OE1	GLU	B	497	-25.105	1.500	-8.565	1.00	49.62	O
ATOM	486	OE2	GLU	B	497	-23.512	2.227	-9.878	1.00	53.93	O1-
ATOM	487	N	GLU	B	498	-22.261	-0.182	-4.400	1.00	19.94	N
ATOM	488	CA	GLU	B	498	-21.524	0.656	-3.472	1.00	20.52	C
ATOM	489	C	GLU	B	498	-20.315	-0.105	-2.949	1.00	18.10	C
ATOM	490	O	GLU	B	498	-19.231	0.450	-2.811	1.00	19.99	O
ATOM	491	CB	GLU	B	498	-22.426	1.079	-2.319	1.00	27.19	C
ATOM	492	CG	GLU	B	498	-22.097	2.407	-1.676	1.00	30.12	C
ATOM	493	CD	GLU	B	498	-22.998	2.702	-0.476	1.00	30.63	C
ATOM	494	OE1	GLU	B	498	-24.161	2.181	-0.451	1.00	25.76	O
ATOM	495	OE2	GLU	B	498	-22.510	3.397	0.455	1.00	27.41	O1-
ATOM	496	N	PHE	B	499	-20.493	-1.392	-2.718	1.00	19.15	N
ATOM	497	CA	PHE	B	499	-19.360	-2.275	-2.373	1.00	20.13	C
ATOM	498	C	PHE	B	499	-18.349	-2.438	-3.513	1.00	20.46	C
ATOM	499	O	PHE	B	499	-17.104	-2.345	-3.312	1.00	18.71	O
ATOM	500	CB	PHE	B	499	-19.906	-3.634	-1.928	1.00	25.56	C
ATOM	501	CG	PHE	B	499	-18.867	-4.733	-1.870	1.00	21.06	C
ATOM	502	CD1	PHE	B	499	-18.027	-4.837	-0.793	1.00	24.29	C
ATOM	503	CD2	PHE	B	499	-18.754	-5.656	-2.896	1.00	21.57	C
ATOM	504	CE1	PHE	B	499	-17.082	-5.851	-0.722	1.00	23.98	C
ATOM	505	CE2	PHE	B	499	-17.812	-6.697	-2.834	1.00	23.92	C
ATOM	506	CZ	PHE	B	499	-16.972	-6.785	-1.733	1.00	24.55	C
ATOM	507	N	VAL	B	500	-18.870	-2.700	-4.716	1.00	18.05	N
ATOM	508	CA	VAL	B	500	-18.028	-2.806	-5.900	1.00	21.30	C
ATOM	509	C	VAL	B	500	-17.190	-1.527	-6.087	1.00	17.89	C
ATOM	510	O	VAL	B	500	-15.998	-1.590	-6.424	1.00	18.39	O
ATOM	511	CB	VAL	B	500	-18.895	-3.132	-7.137	1.00	18.81	C
ATOM	512	CG1	VAL	B	500	-18.129	-2.914	-8.495	1.00	20.80	C
ATOM	513	CG2	VAL	B	500	-19.533	-4.533	-6.981	1.00	19.95	C
ATOM	514	N	ASN	B	501	-17.791	-0.358	-5.844	1.00	18.29	N
ATOM	515	CA	ASN	B	501	-17.055	0.895	-5.932	1.00	19.18	C
ATOM	516	C	ASN	B	501	-15.940	1.001	-4.949	1.00	17.71	C
ATOM	517	O	ASN	B	501	-14.887	1.580	-5.246	1.00	18.52	O
ATOM	518	CB	ASN	B	501	-17.995	2.107	-5.778	1.00	24.05	C
ATOM	519	CG	ASN	B	501	-18.863	2.310	-6.985	1.00	33.74	C
ATOM	520	ND2	ASN	B	501	-19.950	3.086	-6.825	1.00	30.59	N
ATOM	521	OD1	ASN	B	501	-18.593	1.752	-8.053	1.00	35.48	O
ATOM	522	N	ASP	B	502	-16.147	0.478	-3.746	1.00	18.66	N
ATOM	523	CA	ASP	B	502	-15.075	0.453	-2.767	1.00	18.38	C
ATOM	524	C	ASP	B	502	-13.938	-0.419	-3.255	1.00	18.45	C
ATOM	525	O	ASP	B	502	-12.800	0.003	-3.197	1.00	18.82	O
ATOM	526	CB	ASP	B	502	-15.554	-0.003	-1.414	1.00	20.16	C
ATOM	527	CG	ASP	B	502	-16.194	1.147	-0.604	1.00	21.15	C
ATOM	528	OD1	ASP	B	502	-16.285	2.269	-1.145	1.00	20.93	O
ATOM	529	OD2	ASP	B	502	-16.542	0.906	0.567	1.00	24.37	O1-
ATOM	530	N	MET	B	503	-14.234	-1.609	-3.764	1.00	19.08	N
ATOM	531	CA	MET	B	503	-13.150	-2.449	-4.339	1.00	19.53	C
ATOM	532	C	MET	B	503	-12.369	-1.747	-5.433	1.00	18.18	C
ATOM	533	O	MET	B	503	-11.152	-1.757	-5.430	1.00	19.79	O
ATOM	534	CB	MET	B	503	-13.703	-3.723	-4.951	1.00	28.96	C
ATOM	535	CG	MET	B	503	-13.778	-4.799	-4.011	1.00	36.98	C
ATOM	536	SD	MET	B	503	-12.210	-5.685	-3.702	1.00	24.71	S
ATOM	537	CE	MET	B	503	-13.116	-6.719	-2.635	1.00	24.37	C
ATOM	538	N	LYS	B	504	-13.082	-1.135	-6.370	1.00	19.81	N
ATOM	539	CA	LYS	B	504	-12.488	-0.396	-7.466	1.00	20.71	C
ATOM	540	C	LYS	B	504	-11.625	0.758	-6.965	1.00	19.55	C
ATOM	541	O	LYS	B	504	-10.516	0.967	-7.478	1.00	19.25	O
ATOM	542	CB	LYS	B	504	-13.559	0.149	-8.436	1.00	25.10	C

ATOM	543	CG	LYS	B	504	-14.217	-0.907	-9.292	1.00	27.59	C
ATOM	544	CD	LYS	B	504	-15.307	-0.286	-10.196	1.00	37.23	C
ATOM	545	CE	LYS	B	504	-16.077	-1.320	-11.012	1.00	44.06	C
ATOM	546	NZ	LYS	B	504	-17.394	-0.748	-11.505	1.00	47.73	N1+
ATOM	547	N	THR	B	505	-12.121	1.475	-5.967	1.00	18.03	N
ATOM	548	CA	THR	B	505	-11.357	2.536	-5.296	1.00	19.72	C
ATOM	549	C	THR	B	505	-10.050	2.043	-4.687	1.00	19.13	C
ATOM	550	O	THR	B	505	-9.012	2.701	-4.815	1.00	18.84	O
ATOM	551	CB	THR	B	505	-12.196	3.289	-4.215	1.00	21.94	C
ATOM	552	CG2	THR	B	505	-11.320	4.365	-3.500	1.00	21.05	C
ATOM	553	OG1	THR	B	505	-13.287	3.954	-4.854	1.00	22.10	O
ATOM	554	N	MET	B	506	-10.104	0.884	-4.040	1.00	18.22	N
ATOM	555	CA	MET	B	506	-8.891	0.318	-3.464	1.00	19.28	C
ATOM	556	C	MET	B	506	-7.806	0.124	-4.550	1.00	16.00	C
ATOM	557	O	MET	B	506	-6.650	0.509	-4.348	1.00	16.75	O
ATOM	558	CB	MET	B	506	-9.204	-0.982	-2.725	1.00	19.28	C
ATOM	559	CG	MET	B	506	-7.967	-1.609	-2.075	1.00	21.39	C
ATOM	560	SD	MET	B	506	-8.401	-3.045	-1.116	1.00	20.62	S
ATOM	561	CE	MET	B	506	-8.538	-4.248	-2.414	1.00	19.41	C
ATOM	562	N	PHE	B	507	-8.163	-0.479	-5.684	1.00	17.73	N
ATOM	563	CA	PHE	B	507	-7.228	-0.707	-6.791	1.00	16.22	C
ATOM	564	C	PHE	B	507	-6.737	0.582	-7.405	1.00	19.79	C
ATOM	565	O	PHE	B	507	-5.554	0.727	-7.678	1.00	18.67	O
ATOM	566	CB	PHE	B	507	-7.878	-1.560	-7.918	1.00	17.76	C
ATOM	567	CG	PHE	B	507	-8.463	-2.857	-7.430	1.00	18.22	C
ATOM	568	CD1	PHE	B	507	-7.767	-3.654	-6.562	1.00	21.31	C
ATOM	569	CD2	PHE	B	507	-9.702	-3.293	-7.890	1.00	21.72	C
ATOM	570	CE1	PHE	B	507	-8.303	-4.880	-6.124	1.00	19.98	C
ATOM	571	CE2	PHE	B	507	-10.236	-4.504	-7.439	1.00	20.55	C
ATOM	572	CZ	PHE	B	507	-9.552	-5.268	-6.543	1.00	19.68	C
ATOM	573	N	ARG	B	508	-7.655	1.518	-7.656	1.00	21.91	N
ATOM	574	CA	ARG	B	508	-7.305	2.811	-8.242	1.00	21.48	C
ATOM	575	C	ARG	B	508	-6.342	3.581	-7.336	1.00	21.25	C
ATOM	576	O	ARG	B	508	-5.342	4.147	-7.822	1.00	20.39	O
ATOM	577	CB	ARG	B	508	-8.593	3.614	-8.505	1.00	22.15	C
ATOM	578	CG	ARG	B	508	-8.461	4.824	-9.362	1.00	36.98	C
ATOM	579	CD	ARG	B	508	-9.862	5.436	-9.657	1.00	37.09	C
ATOM	580	NE	ARG	B	508	-10.510	5.832	-8.406	1.00	55.94	N
ATOM	581	CZ	ARG	B	508	-11.664	5.350	-7.930	1.00	51.31	C
ATOM	582	NH1	ARG	B	508	-12.099	5.796	-6.751	1.00	37.97	N
ATOM	583	NH2	ARG	B	508	-12.393	4.454	-8.616	1.00	39.32	N1+
ATOM	584	N	ASN	B	509	-6.623	3.604	-6.025	1.00	20.68	N
ATOM	585	CA	ASN	B	509	-5.706	4.219	-5.066	1.00	20.18	C
ATOM	586	C	ASN	B	509	-4.296	3.640	-5.181	1.00	22.82	C
ATOM	587	O	ASN	B	509	-3.303	4.347	-5.044	1.00	21.66	O
ATOM	588	CB	ASN	B	509	-6.136	3.997	-3.601	1.00	18.16	C
ATOM	589	CG	ASN	B	509	-7.388	4.750	-3.213	1.00	20.28	C
ATOM	590	ND2	ASN	B	509	-8.008	4.312	-2.123	1.00	19.58	N
ATOM	591	OD1	ASN	B	509	-7.839	5.667	-3.909	1.00	20.88	O
ATOM	592	N	CYS	B	510	-4.207	2.331	-5.332	1.00	20.00	N
ATOM	593	CA	CYS	B	510	-2.880	1.682	-5.381	1.00	17.96	C
ATOM	594	C	CYS	B	510	-2.061	2.168	-6.559	1.00	19.12	C
ATOM	595	O	CYS	B	510	-0.900	2.566	-6.405	1.00	20.04	O
ATOM	596	CB	CYS	B	510	-3.030	0.180	-5.416	1.00	18.46	C
ATOM	597	SG	CYS	B	510	-1.424	-0.640	-5.472	1.00	22.05	S
ATOM	598	N	ARG	B	511	-2.673	2.197	-7.731	1.00	22.35	N
ATOM	599	CA	ARG	B	511	-2.012	2.666	-8.919	1.00	23.03	C
ATOM	600	C	ARG	B	511	-1.670	4.157	-8.806	1.00	23.36	C
ATOM	601	O	ARG	B	511	-0.623	4.579	-9.278	1.00	25.50	O
ATOM	602	CB	ARG	B	511	-2.924	2.430	-10.113	1.00	26.11	C
ATOM	603	CG	ARG	B	511	-2.346	2.906	-11.422	1.00	32.14	C
ATOM	604	CD	ARG	B	511	-3.153	2.362	-12.621	1.00	37.22	C
ATOM	605	NE	ARG	B	511	-2.388	1.344	-13.370	1.00	40.09	N

ATOM	606	CZ	ARG	B	511	-2.580	0.018	-13.317	1.00	38.93	C
ATOM	607	NH1	ARG	B	511	-1.810	-0.781	-14.051	1.00	37.19	N
ATOM	608	NH2	ARG	B	511	-3.525	-0.528	-12.543	1.00	33.42	N1+
ATOM	609	N	LYS	B	512	-2.552	4.939	-8.175	1.00	20.40	N
ATOM	610	CA	LYS	B	512	-2.356	6.387	-8.079	1.00	28.20	C
ATOM	611	C	LYS	B	512	-1.188	6.668	-7.141	1.00	27.78	C
ATOM	612	O	LYS	B	512	-0.322	7.493	-7.452	1.00	30.47	O
ATOM	613	CB	LYS	B	512	-3.632	7.083	-7.604	1.00	30.83	C
ATOM	614	CG	LYS	B	512	-3.485	8.436	-6.921	1.00	39.11	C
ATOM	615	CD	LYS	B	512	-3.236	9.560	-7.904	1.00	60.33	C
ATOM	616	CE	LYS	B	512	-3.782	10.884	-7.382	1.00	63.25	C
ATOM	617	NZ	LYS	B	512	-4.656	11.514	-8.403	1.00	74.76	N1+
ATOM	618	N	TYR	B	513	-1.149	5.971	-6.011	1.00	22.13	N
ATOM	619	CA	TYR	B	513	-0.116	6.222	-5.025	1.00	22.40	C
ATOM	620	C	TYR	B	513	1.219	5.621	-5.450	1.00	26.76	C
ATOM	621	O	TYR	B	513	2.222	6.319	-5.458	1.00	23.12	O
ATOM	622	CB	TYR	B	513	-0.539	5.766	-3.611	1.00	22.93	C
ATOM	623	CG	TYR	B	513	0.537	6.032	-2.588	1.00	24.38	C
ATOM	624	CD1	TYR	B	513	0.832	7.330	-2.194	1.00	23.88	C
ATOM	625	CD2	TYR	B	513	1.317	5.001	-2.077	1.00	25.09	C
ATOM	626	CE1	TYR	B	513	1.835	7.598	-1.292	1.00	28.19	C
ATOM	627	CE2	TYR	B	513	2.340	5.258	-1.172	1.00	30.92	C
ATOM	628	CZ	TYR	B	513	2.578	6.574	-0.776	1.00	31.57	C
ATOM	629	OH	TYR	B	513	3.598	6.894	0.107	1.00	29.70	O
ATOM	630	N	ASN	B	514	1.237	4.347	-5.833	1.00	21.81	N
ATOM	631	CA	ASN	B	514	2.489	3.639	-6.090	1.00	23.58	C
ATOM	632	C	ASN	B	514	3.046	3.754	-7.529	1.00	25.17	C
ATOM	633	O	ASN	B	514	4.235	3.544	-7.754	1.00	23.34	O
ATOM	634	CB	ASN	B	514	2.290	2.180	-5.756	1.00	21.74	C
ATOM	635	CG	ASN	B	514	1.964	1.954	-4.314	1.00	24.71	C
ATOM	636	ND2	ASN	B	514	3.035	2.166	-3.393	1.00	21.71	O
ATOM	637	OD1	ASN	B	514	0.829	1.569	-3.956	1.00	24.46	N
ATOM	638	N	GLY	B	515	2.213	4.129	-8.476	1.00	24.17	N
ATOM	639	CA	GLY	B	515	2.656	4.234	-9.866	1.00	24.25	C
ATOM	640	C	GLY	B	515	2.309	3.047	-10.735	1.00	28.07	C
ATOM	641	O	GLY	B	515	2.139	1.903	-10.258	1.00	20.96	O
ATOM	642	N	GLU	B	516	2.248	3.318	-12.031	1.00	29.60	N
ATOM	643	CA	GLU	B	516	1.848	2.327	-13.022	1.00	34.87	C
ATOM	644	C	GLU	B	516	2.612	1.008	-12.929	1.00	26.17	C
ATOM	645	O	GLU	B	516	2.025	-0.072	-13.102	1.00	30.02	O
ATOM	646	CB	GLU	B	516	2.047	2.935	-14.431	1.00	40.26	C
ATOM	647	CG	GLU	B	516	1.678	2.047	-15.603	1.00	55.25	C
ATOM	648	CD	GLU	B	516	0.264	1.511	-15.505	1.00	67.88	C
ATOM	649	OE1	GLU	B	516	-0.632	2.255	-15.032	1.00	65.44	O
ATOM	650	OE2	GLU	B	516	0.054	0.338	-15.891	1.00	49.59	O1-
ATOM	651	N	SER	B	517	3.912	1.083	-12.710	1.00	27.35	N
ATOM	652	CA	SER	B	517	4.807	-0.076	-12.852	1.00	26.92	C
ATOM	653	C	SER	B	517	5.273	-0.610	-11.493	1.00	24.76	C
ATOM	654	O	SER	B	517	6.151	-1.463	-11.422	1.00	28.33	O
ATOM	655	CB	ASER	B	517	5.976	0.293	-13.772	0.50	31.19	C
ATOM	656	OG	ASER	B	517	5.487	0.611	-15.074	0.50	28.90	O
ATOM	657	N	SER	B	518	4.677	-0.096	-10.420	1.00	22.62	N
ATOM	658	CA	SER	B	518	4.999	-0.532	-9.077	1.00	22.32	C
ATOM	659	C	SER	B	518	4.708	-2.018	-8.947	1.00	22.38	C
ATOM	660	O	SER	B	518	3.730	-2.528	-9.488	1.00	19.33	O
ATOM	661	CB	SER	B	518	4.147	0.215	-8.071	1.00	19.25	C
ATOM	662	OG	SER	B	518	4.350	-0.263	-6.759	1.00	21.56	O
ATOM	663	N	GLU	B	519	5.554	-2.699	-8.191	1.00	23.61	N
ATOM	664	CA	GLU	B	519	5.286	-4.065	-7.776	1.00	24.81	C
ATOM	665	C	GLU	B	519	3.942	-4.163	-7.028	1.00	22.08	C
ATOM	666	O	GLU	B	519	3.235	-5.160	-7.123	1.00	17.92	O
ATOM	667	CB	GLU	B	519	6.436	-4.555	-6.891	1.00	25.12	C
ATOM	668	CG	GLU	B	519	7.765	-4.670	-7.680	1.00	25.18	C

ATOM	669	CD	GLU	B	519	7.606	-5.540	-8.872	1.00	29.44	C
ATOM	670	OE1	GLU	B	519	7.311	-6.726	-8.642	1.00	36.19	O
ATOM	671	OE2	GLU	B	519	7.709	-5.068	-10.026	1.00	28.15	O1-
ATOM	672	N	TYR	B	520	3.585	-3.117	-6.313	1.00	19.75	N
ATOM	673	CA	TYR	B	520	2.306	-3.085	-5.621	1.00	18.02	C
ATOM	674	C	TYR	B	520	1.157	-2.991	-6.595	1.00	17.46	C
ATOM	675	O	TYR	B	520	0.115	-3.558	-6.332	1.00	19.03	O
ATOM	676	CB	TYR	B	520	2.254	-1.936	-4.600	1.00	18.48	C
ATOM	677	CG	TYR	B	520	3.244	-2.148	-3.502	1.00	22.48	C
ATOM	678	CD1	TYR	B	520	3.011	-3.102	-2.503	1.00	24.65	C
ATOM	679	CD2	TYR	B	520	4.434	-1.420	-3.456	1.00	27.12	C
ATOM	680	CE1	TYR	B	520	3.936	-3.318	-1.475	1.00	25.36	C
ATOM	681	CE2	TYR	B	520	5.382	-1.631	-2.433	1.00	27.36	C
ATOM	682	CZ	TYR	B	520	5.129	-2.574	-1.445	1.00	33.29	C
ATOM	683	OH	TYR	B	520	6.093	-2.794	-0.473	1.00	27.49	O
ATOM	684	N	THR	B	521	1.339	-2.282	-7.708	1.00	17.78	N
ATOM	685	CA	THR	B	521	0.292	-2.202	-8.726	1.00	17.27	C
ATOM	686	C	THR	B	521	0.127	-3.521	-9.446	1.00	19.27	C
ATOM	687	O	THR	B	521	-0.991	-3.900	-9.774	1.00	21.59	O
ATOM	688	CB	THR	B	521	0.526	-0.996	-9.685	1.00	18.92	C
ATOM	689	CG2	THR	B	521	-0.610	-0.854	-10.716	1.00	18.74	C
ATOM	690	OG1	THR	B	521	0.630	0.189	-8.897	1.00	22.35	O
ATOM	691	N	LYS	B	522	1.221	-4.241	-9.688	1.00	20.06	N
ATOM	692	CA	LYS	B	522	1.130	-5.574	-10.256	1.00	23.04	C
ATOM	693	C	LYS	B	522	0.306	-6.492	-9.334	1.00	21.90	C
ATOM	694	O	LYS	B	522	-0.498	-7.291	-9.794	1.00	18.93	O
ATOM	695	CB	ALYS	B	522	2.528	-6.158	-10.483	0.50	24.47	C
ATOM	696	CG	ALYS	B	522	3.322	-5.445	-11.588	0.50	33.71	C
ATOM	697	CD	ALYS	B	522	4.769	-5.950	-11.661	0.50	38.67	C
ATOM	698	CE	ALYS	B	522	5.482	-5.448	-12.916	0.50	44.03	C
ATOM	699	NZ	ALYS	B	522	5.791	-3.995	-12.866	0.50	47.50	N1+
ATOM	700	N	MET	B	523	0.528	-6.396	-8.028	1.00	20.29	N
ATOM	701	CA	MET	B	523	-0.262	-7.157	-7.083	1.00	18.00	C
ATOM	702	C	MET	B	523	-1.733	-6.744	-7.156	1.00	17.76	C
ATOM	703	O	MET	B	523	-2.633	-7.590	-7.115	1.00	18.11	O
ATOM	704	CB	MET	B	523	0.280	-6.980	-5.673	1.00	18.53	C
ATOM	705	CG	MET	B	523	1.735	-7.533	-5.544	1.00	24.23	C
ATOM	706	SD	MET	B	523	2.525	-7.111	-3.973	1.00	25.40	S
ATOM	707	CE	MET	B	523	1.715	-8.332	-3.031	1.00	21.03	C
ATOM	708	N	SER	B	524	-1.968	-5.444	-7.204	1.00	19.31	N
ATOM	709	CA	SER	B	524	-3.326	-4.919	-7.270	1.00	19.77	C
ATOM	710	C	SER	B	524	-4.025	-5.456	-8.520	1.00	19.38	C
ATOM	711	O	SER	B	524	-5.207	-5.815	-8.486	1.00	19.78	O
ATOM	712	CB	SER	B	524	-3.271	-3.379	-7.295	1.00	20.92	C
ATOM	713	OG	SER	B	524	-4.565	-2.842	-7.428	1.00	21.29	O
ATOM	714	N	ASP	B	525	-3.291	-5.512	-9.635	1.00	16.42	N
ATOM	715	CA	ASP	B	525	-3.871	-6.003	-10.892	1.00	18.34	C
ATOM	716	C	ASP	B	525	-4.255	-7.489	-10.807	1.00	18.54	C
ATOM	717	O	ASP	B	525	-5.289	-7.878	-11.331	1.00	20.32	O
ATOM	718	CB	ASP	B	525	-2.941	-5.799	-12.064	1.00	18.84	C
ATOM	719	CG	ASP	B	525	-2.832	-4.341	-12.524	1.00	26.52	C
ATOM	720	OD1	ASP	B	525	-3.643	-3.457	-12.160	1.00	21.83	O
ATOM	721	OD2	ASP	B	525	-1.890	-4.082	-13.281	1.00	26.22	O1-
ATOM	722	N	ASN	B	526	-3.437	-8.309	-10.149	1.00	21.39	N
ATOM	723	CA	ASN	B	526	-3.813	-9.692	-9.866	1.00	24.71	C
ATOM	724	C	ASN	B	526	-5.043	-9.798	-8.978	1.00	20.69	C
ATOM	725	O	ASN	B	526	-5.912	-10.644	-9.237	1.00	21.47	O
ATOM	726	CB	ASN	B	526	-2.674	-10.463	-9.202	1.00	26.72	C
ATOM	727	CG	ASN	B	526	-1.716	-11.007	-10.178	1.00	32.31	C
ATOM	728	ND2	ASN	B	526	-0.443	-10.956	-9.829	1.00	35.31	N
ATOM	729	OD1	ASN	B	526	-2.093	-11.464	-11.266	1.00	32.17	O
ATOM	730	N	LEU	B	527	-5.123	-8.965	-7.934	1.00	20.30	N
ATOM	731	CA	LEU	B	527	-6.303	-8.969	-7.057	1.00	22.51	C

ATOM	732	C	LEU	B	527	-7.555	-8.519	-7.798	1.00	21.86	C
ATOM	733	O	LEU	B	527	-8.658	-9.036	-7.565	1.00	21.32	O
ATOM	734	CB	LEU	B	527	-6.157	-8.050	-5.832	1.00	24.90	C
ATOM	735	CG	LEU	B	527	-5.497	-8.547	-4.568	1.00	32.86	C
ATOM	736	CD1	LEU	B	527	-5.719	-7.471	-3.452	1.00	28.23	C
ATOM	737	CD2	LEU	B	527	-6.062	-9.917	-4.209	1.00	28.39	C
ATOM	738	N	GLU	B	528	-7.377	-7.537	-8.664	1.00	21.02	N
ATOM	739	CA	GLU	B	528	-8.463	-7.032	-9.456	1.00	20.49	C
ATOM	740	C	GLU	B	528	-9.011	-8.119	-10.400	1.00	20.20	C
ATOM	741	O	GLU	B	528	-10.217	-8.274	-10.536	1.00	19.76	O
ATOM	742	CB	GLU	B	528	-8.040	-5.773	-10.215	1.00	22.31	C
ATOM	743	CG	GLU	B	528	-9.171	-5.141	-11.000	1.00	24.03	C
ATOM	744	CD	GLU	B	528	-8.898	-3.722	-11.531	1.00	27.16	C
ATOM	745	OE1	GLU	B	528	-7.839	-3.120	-11.315	1.00	30.22	O
ATOM	746	OE2	GLU	B	528	-9.795	-3.190	-12.188	1.00	38.18	O1-
ATOM	747	N	ARG	B	529	-8.142	-8.849	-11.094	1.00	19.79	N
ATOM	748	CA	ARG	B	529	-8.580	-10.025	-11.829	1.00	19.41	C
ATOM	749	C	ARG	B	529	-9.333	-11.049	-10.946	1.00	19.69	C
ATOM	750	O	ARG	B	529	-10.412	-11.556	-11.317	1.00	19.94	O
ATOM	751	CB	ARG	B	529	-7.391	-10.671	-12.535	1.00	21.63	C
ATOM	752	CG	ARG	B	529	-7.032	-9.997	-13.812	1.00	23.34	C
ATOM	753	CD	ARG	B	529	-5.879	-10.704	-14.548	1.00	24.50	C
ATOM	754	NE	ARG	B	529	-4.606	-10.582	-13.846	1.00	27.51	N
ATOM	755	CZ	ARG	B	529	-3.740	-9.581	-14.027	1.00	25.38	C
ATOM	756	NH1	ARG	B	529	-2.616	-9.576	-13.355	1.00	29.50	N
ATOM	757	NH2	ARG	B	529	-3.982	-8.597	-14.890	1.00	28.38	N1+
ATOM	758	N	CYS	B	530	-8.792	-11.341	-9.770	1.00	22.92	N
ATOM	759	CA	CYS	B	530	-9.434	-12.251	-8.829	1.00	22.81	C
ATOM	760	C	CYS	B	530	-10.866	-11.790	-8.498	1.00	26.45	C
ATOM	761	O	CYS	B	530	-11.797	-12.589	-8.479	1.00	20.91	O
ATOM	762	CB	CYS	B	530	-8.579	-12.382	-7.571	1.00	25.32	C
ATOM	763	SG	CYS	B	530	-9.318	-13.310	-6.227	1.00	24.50	S
ATOM	764	N	PHE	B	531	-11.011	-10.491	-8.272	1.00	22.01	N
ATOM	765	CA	PHE	B	531	-12.292	-9.836	-7.992	1.00	21.18	C
ATOM	766	C	PHE	B	531	-13.286	-9.952	-9.133	1.00	20.91	C
ATOM	767	O	PHE	B	531	-14.412	-10.397	-8.915	1.00	21.73	O
ATOM	768	CB	PHE	B	531	-12.038	-8.348	-7.699	1.00	22.39	C
ATOM	769	CG	PHE	B	531	-13.283	-7.518	-7.604	1.00	21.09	C
ATOM	770	CD1	PHE	B	531	-14.200	-7.753	-6.581	1.00	26.66	C
ATOM	771	CD2	PHE	B	531	-13.521	-6.501	-8.500	1.00	23.82	C
ATOM	772	CE1	PHE	B	531	-15.365	-6.950	-6.476	1.00	26.00	C
ATOM	773	CE2	PHE	B	531	-14.693	-5.709	-8.411	1.00	25.88	C
ATOM	774	CZ	PHE	B	531	-15.591	-5.938	-7.395	1.00	23.60	C
ATOM	775	N	HIS	B	532	-12.844	-9.603	-10.335	1.00	24.83	N
ATOM	776	CA	HIS	B	532	-13.695	-9.671	-11.512	1.00	25.18	C
ATOM	777	C	HIS	B	532	-14.228	-11.080	-11.768	1.00	25.78	C
ATOM	778	O	HIS	B	532	-15.368	-11.246	-12.179	1.00	29.41	O
ATOM	779	CB	HIS	B	532	-12.984	-9.136	-12.745	1.00	28.90	C
ATOM	780	CG	HIS	B	532	-12.831	-7.649	-12.739	1.00	31.12	C
ATOM	781	ND1	HIS	B	532	-13.594	-6.678	-12.180	1.00	31.67	N
ATOM	782	CD2	HIS	B	532	-11.766	-7.007	-13.334	1.00	37.29	C
ATOM	783	NE2	HIS	B	532	-11.889	-5.702	-13.157	1.00	39.25	N
ATOM	784	CE1	HIS	B	532	-12.985	-5.476	-12.450	1.00	31.85	C
ATOM	785	N	ARG	B	533	-13.380	-12.075	-11.539	1.00	23.93	N
ATOM	786	CA	ARG	B	533	-13.743	-13.453	-11.691	1.00	25.83	C
ATOM	787	C	ARG	B	533	-14.742	-13.828	-10.620	1.00	25.72	C
ATOM	788	O	ARG	B	533	-15.766	-14.428	-10.926	1.00	24.71	O
ATOM	789	CB	ARG	B	533	-12.515	-14.377	-11.618	1.00	24.82	C
ATOM	790	CG	ARG	B	533	-12.862	-15.847	-11.560	1.00	26.83	C
ATOM	791	CD	ARG	B	533	-13.711	-16.260	-12.748	1.00	29.43	C
ATOM	792	NE	ARG	B	533	-13.988	-17.699	-12.830	1.00	28.32	N
ATOM	793	CZ	ARG	B	533	-14.761	-18.233	-13.769	1.00	30.32	C
ATOM	794	NH1	ARG	B	533	-15.344	-17.454	-14.675	1.00	34.79	N

ATOM	795	NH2	ARG	B	533	-14.968	-19.533	-13.813	1.00	30.23	N1+
ATOM	796	N	ALA	B	534	-14.457	-13.465	-9.370	1.00	24.06	N
ATOM	797	CA	ALA	B	534	-15.390	-13.683	-8.260	1.00	24.13	C
ATOM	798	C	ALA	B	534	-16.785	-13.085	-8.536	1.00	23.71	C
ATOM	799	O	ALA	B	534	-17.814	-13.684	-8.222	1.00	27.45	O
ATOM	800	CB	ALA	B	534	-14.802	-13.092	-6.960	1.00	22.26	C
ATOM	801	N	MET	B	535	-16.814	-11.920	-9.151	1.00	24.34	N
ATOM	802	CA	MET	B	535	-18.070	-11.276	-9.487	1.00	25.98	C
ATOM	803	C	MET	B	535	-18.849	-11.976	-10.614	1.00	30.40	C
ATOM	804	O	MET	B	535	-20.034	-11.669	-10.814	1.00	30.04	O
ATOM	805	CB	MET	B	535	-17.839	-9.795	-9.838	1.00	24.69	C
ATOM	806	CG	MET	B	535	-17.372	-8.951	-8.661	1.00	23.09	C
ATOM	807	SD	MET	B	535	-18.608	-8.685	-7.385	1.00	29.88	S
ATOM	808	CE	MET	B	535	-19.866	-7.837	-8.364	1.00	24.71	C
ATOM	809	N	MET	B	536	-18.216	-12.890	-11.361	1.00	29.21	N
ATOM	810	CA	MET	B	536	-18.936	-13.670	-12.417	1.00	36.23	C
ATOM	811	C	MET	B	536	-19.704	-14.891	-11.855	1.00	38.97	C
ATOM	812	O	MET	B	536	-20.809	-15.224	-12.309	1.00	51.73	O
ATOM	813	CB	MET	B	536	-17.948	-14.233	-13.452	1.00	32.52	C
ATOM	814	CG	MET	B	536	-17.031	-13.238	-14.112	1.00	30.14	C
ATOM	815	SD	MET	B	536	-15.863	-14.064	-15.229	1.00	30.08	S
ATOM	816	CE	MET	B	536	-17.008	-14.876	-16.348	1.00	35.82	C
ATOM	817	N	LYS	B	537	-19.071	-15.566	-10.890	1.00	48.72	N
ATOM	818	CA	LYS	B	537	-19.286	-16.996	-10.598	1.00	70.81	C
ATOM	819	C	LYS	B	537	-19.636	-17.202	-9.129	1.00	62.78	C
ATOM	820	OXT	LYS	B	537	-18.836	-17.813	-8.378	1.00	62.78	O1-
ATOM	821	O	LYS	B	537	-20.695	-16.775	-8.673	1.00	77.30	O
ATOM	822	CB	LYS	B	537	-18.030	-17.773	-11.034	1.00	51.31	C
ATOM	823	CG	LYS	B	537	-18.062	-19.285	-10.740	1.00	0.00	C
ATOM	824	CD	LYS	B	537	-19.237	-20.048	-11.377	1.00	0.00	C
ATOM	825	CE	LYS	B	537	-19.334	-19.886	-12.901	1.00	0.00	C
ATOM	826	NZ	LYS	B	537	-18.162	-20.460	-13.607	1.00	0.00	N1+
TER	827		LYS	B	537						
HETATM	828	N2	LIG		0	0.357	-0.345	0.287	1.00	0.00	N
HETATM	829	N3	LIG		0	3.529	1.432	-0.449	1.00	0.00	N
HETATM	830	C13	LIG		0	2.208	-1.154	1.590	1.00	0.00	C
HETATM	831	C14	LIG		0	0.911	-1.212	1.231	1.00	0.00	C
HETATM	832	C15	LIG		0	-1.039	-0.537	-0.080	1.00	0.00	C
HETATM	833	C16	LIG		0	1.112	0.688	-0.316	1.00	0.00	C
HETATM	834	C17	LIG		0	2.512	0.663	0.051	1.00	0.00	C
HETATM	835	C18	LIG		0	3.067	-0.209	0.966	1.00	0.00	C
HETATM	836	C19	LIG		0	4.452	0.035	1.030	1.00	0.00	C
HETATM	837	C20	LIG		0	4.710	1.065	0.147	1.00	0.00	C
HETATM	838	O22	LIG		0	0.637	1.521	-1.083	1.00	0.00	O
HETATM	839	C	LIG		0	2.647	-2.113	2.636	1.00	0.00	C
HETATM	840	O	LIG		0	2.414	-3.313	2.532	1.00	0.00	O
HETATM	841	N	LIG		0	3.263	-1.506	3.713	1.00	0.00	N
HETATM	842	N	LIG		0	4.152	-4.552	6.558	1.00	0.00	N1+
HETATM	843	C	LIG		0	4.585	-5.370	7.744	1.00	0.00	C
HETATM	844	C	LIG		0	5.327	-3.885	5.885	1.00	0.00	C
HETATM	845	C	LIG		0	4.857	-3.187	4.617	1.00	0.00	C
HETATM	846	C	LIG		0	3.719	-2.207	4.908	1.00	0.00	C
HETATM	847	C	LIG		0	2.570	-2.876	5.669	1.00	0.00	C
HETATM	848	C	LIG		0	3.071	-3.563	6.930	1.00	0.00	C
TER	849		LIG		0						
HETATM	850	N2	LIG		0	0.169	-0.250	0.414	1.00	0.00	N
HETATM	851	N3	LIG		0	3.586	1.006	-0.268	1.00	0.00	N
HETATM	852	C13	LIG		0	1.781	-1.015	2.035	1.00	0.00	C
HETATM	853	C14	LIG		0	0.524	-0.987	1.544	1.00	0.00	C
HETATM	854	C15	LIG		0	-1.192	-0.362	-0.094	1.00	0.00	C
HETATM	855	C16	LIG		0	1.095	0.577	-0.257	1.00	0.00	C
HETATM	856	C17	LIG		0	2.445	0.445	0.241	1.00	0.00	C
HETATM	857	C18	LIG		0	2.807	-0.320	1.332	1.00	0.00	C

HETATM	858	C19	LIG	0	4.201	-0.221	1.496	1.00	0.00	C
HETATM	859	C20	LIG	0	4.660	0.605	0.489	1.00	0.00	C
HETATM	860	O22	LIG	0	0.790	1.329	-1.178	1.00	0.00	O
HETATM	861	C	LIG	0	2.061	-1.819	3.266	1.00	0.00	C
HETATM	862	O	LIG	0	3.063	-2.520	3.366	1.00	0.00	O
HETATM	863	N	LIG	0	1.105	-1.655	4.256	1.00	0.00	N
HETATM	864	N	LIG	0	0.316	-2.333	8.335	1.00	0.00	N1+
HETATM	865	C	LIG	0	0.159	-2.791	9.760	1.00	0.00	C
HETATM	866	C	LIG	0	-0.328	-3.298	7.370	1.00	0.00	C
HETATM	867	C	LIG	0	-0.290	-2.704	5.971	1.00	0.00	C
HETATM	868	C	LIG	0	1.137	-2.347	5.540	1.00	0.00	C
HETATM	869	C	LIG	0	1.830	-1.467	6.583	1.00	0.00	C
HETATM	870	C	LIG	0	1.756	-2.058	7.983	1.00	0.00	C
TER	871		LIG	0						
HETATM	872	N2	LIG	0	0.610	-0.485	0.429	1.00	0.00	N
HETATM	873	N3	LIG	0	3.642	1.384	-0.571	1.00	0.00	N
HETATM	874	C13	LIG	0	2.559	-1.150	1.687	1.00	0.00	C
HETATM	875	C14	LIG	0	1.243	-1.264	1.400	1.00	0.00	C
HETATM	876	C15	LIG	0	-0.803	-0.719	0.172	1.00	0.00	C
HETATM	877	C16	LIG	0	1.296	0.506	-0.303	1.00	0.00	C
HETATM	878	C17	LIG	0	2.706	0.571	0.007	1.00	0.00	C
HETATM	879	C18	LIG	0	3.344	-0.201	0.961	1.00	0.00	C
HETATM	880	C19	LIG	0	4.697	0.197	0.992	1.00	0.00	C
HETATM	881	C20	LIG	0	4.857	1.170	0.026	1.00	0.00	C
HETATM	882	O22	LIG	0	0.756	1.249	-1.118	1.00	0.00	O
HETATM	883	C	LIG	0	3.057	-2.041	2.782	1.00	0.00	C
HETATM	884	O	LIG	0	2.317	-2.389	3.702	1.00	0.00	O
HETATM	885	N	LIG	0	4.370	-2.458	2.667	1.00	0.00	N
HETATM	886	N	LIG	0	7.195	-4.054	5.432	1.00	0.00	N1+
HETATM	887	C	LIG	0	7.931	-4.870	6.459	1.00	0.00	C
HETATM	888	C	LIG	0	5.926	-3.462	5.998	1.00	0.00	C
HETATM	889	C	LIG	0	5.306	-2.538	4.960	1.00	0.00	C
HETATM	890	C	LIG	0	5.003	-3.305	3.671	1.00	0.00	C
HETATM	891	C	LIG	0	6.286	-3.940	3.128	1.00	0.00	C
HETATM	892	C	LIG	0	6.946	-4.839	4.166	1.00	0.00	C

Supporting Information References:

- 1) Flynn, M.; Huang, O.; Poy, F.; Oppikofer, M.; Bellon, S.; Tang, Y.; Cochran, A.G. A subset of human bromodomains recognizes butyryllysine and crotonyllysine histonepeptide modifications. *Structure* **2015**, *23*, 1801–1814.
- 2) Crawford, T. D.; Tsui, V.; Flynn, E. M.; Wang, S.; Taylor, A. M.; Côté, A.; Audia, J. E.; Beresini, M. H.; Burdick, D. J.; Cummings, R. T.; Dakin, L. A.; Duplessis, M.; Good, A.

- C.; Hewitt, M. C.; Huang, H.-R.; Jayaram, H.; Kiefer, J. R.; Jiang, Y.; Murray, J. M.; Nasveschuk, C. G.; Pardo, E.; Poy, F.; Romero, F. A.; Tang, Y.; Wang, J.; Xu, Z.; Zawadzke, L. E.; Zhu, X.; Albrecht, B. K.; Magnuson, S. R.; Bellon, S. F.; Cochran, A. G. Diving Into the water: Inducible binding conformations for BRD4, TAF1(2), BRD9, and CECR2 bromodomains. *J. Med. Chem.* **2016**, *59*, 5391–5402.
- 3) Albrecht, B. K.; Gehling, V. S.; Hewitt, M. C.; Vaswani, R. G.; Côté, A.; Leblanc, Y.; Nasveschuk, C. G.; Bellon, S.; Bergeron, L.; Campbell, R.; Cantone, N.; Cooper, M. R.; Cummings, R. T.; Jayaram, H.; Joshi, S.; Mertz, J. A.; Neis, A.; Normant, E.; O'Meara, M.; Pardo, E.; Poy, F.; Sandy, P.; Supko, J.; Sims, R. J. 3rd; Harmange, J. C.; Taylor, A. M.; Audia, J. E. Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials. *J. Med. Chem.* **2016**, *59*, 1330–1339.
- 4) Ghosh, S.; Taylor, A.; Chin, M.; Huang, H.-R.; Conery, A. R.; Mertz, J. A.; Salmeron, A.; Dakle, P. J.; Mele, D.; Cote, A.; Jayaram, H.; Setser, J. W.; Poy, F.; Hatzivassiliou, G.; DeAlmeida-Nagata, D.; Sandy, P.; Hatton, C.; Romero, F. A.; Chiang, E.; Reimer, T.; Crawford, T.; Pardo, E.; Watson, V. G.; Tsui, V.; Cochran, A. G.; Zawadzke, L.; Harmange, J.-C.; Auida, J. E.; Bryant, B. M.; Cummings, R. T.; Magnuson, S. R.; Grogan, J. L.; Bellon, S. F.; Albrecht, B. K.; Simms III, R. J.; Lora, J. M. Regulatory T Cell modulation by CBP/EP300 bromodomain inhibition. *J. Biol. Chem.* **2016**, *291*, 13014–13027.
- 5) Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. *Meth. Enzymol.* **1997**, *276*, 307-326.
- 6) McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., & Read, R.J. Phaser crystallographic software. *J. Appl. Cryst.* **2007**, *40*, 658-674.

- 7) Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta crystallographica. Section D, Biological crystallography* **2004**, 60, 2126-2132.
- 8) Bricogne, G., Blanc, E., Brandl, M., Flensburg, C., Keller, P., Paciorek, W., Roversi, P., Sharff, A., Smart, O., Vonnrhein, C. & Womack, T. BUSTER. <http://www.globalphasing.com>. **2011**
- 9) Bricogne, G. & Irwin, J. (1996). Proceedings of the CCP4 Study Weekend. Macromolecular Refinement, edited by E. Dodson, M. Moore, A. Ralph & S. Bailey, pp. 85-92. Warrington: Daresbury Laboratory.